Microarray analysis of bone marrow-derived macrophage cells treated with Kdo2-lipid A (KLA) and ATP

Search by fold change ratio | Search by KEGG pathway | Search by LIPID MAPS lipid pathway

Kdo2-Lipid A / ATP gene array data - treatment:control ratios

KEGG pathway: HTLV-I infection (mmu05166)

Legend:graph_icon: View data/graphs for replicates
Gene symbol    Time course plot Accession Description Treatment 15min 30min 1hr 2hr 4hr 8hr 20hr
14927508
3
KLA  ATP  ATP+KLA
 149275083 Unknown KLA .74 .68 .68 .77 .71 .85 .69
ATP .85 .69 1.26 .89 .89 1.26 .64
KLA/ATP .64 .63 1.07 .96 1.39 1.07 .82
1500003O
03Rik
KLA  ATP  ATP+KLA
 NM_019769 RIKEN cDNA 1500003O03 gene (1500003O03Rik), mRNA [NM_019769] KLA .92 .89 .89 .86 .85 .92 1.08
ATP 1.01 1.16 1.16 1.53 1.70 3.33 2.09
KLA/ATP .89 .97 .93 1.17 1.19 2.86 2.57
1700009N
14Rik
KLA  ATP  ATP+KLA
 NM_001081095 RIKEN cDNA 1700009N14 gene (1700009N14Rik), mRNA [NM_001081095] KLA .94 .99 1.04 1.06 1.04 1.00 .93
ATP 1.03 1.12 1.03 1.00 .89 1.04 .99
KLA/ATP .98 .94 1.05 1.03 .98 .95 1.02
2010110P
09Rik
KLA  ATP  ATP+KLA
 NM_027363 RIKEN cDNA 2010110P09 gene (2010110P09Rik), mRNA [NM_027363] KLA .99 .98 1.02 .99 .94 1.01 1.01
ATP 1.04 1.05 .97 1.05 .95 .98 .95
KLA/ATP .93 1.00 1.02 .97 1.01 .96 .97
Adcy1
KLA  ATP  ATP+KLA
 BC050125 adenylate cyclase 1, mRNA (cDNA clone IMAGE:30015692). [BC050125] KLA 1.05 1.03 .98 1.04 1.05 1.09 1.10
ATP .90 1.02 .99 .97 1.03 .95 1.01
KLA/ATP .99 1.04 .90 .98 .98 1.00 1.03
Adcy1
KLA  ATP  ATP+KLA
 NM_009622 adenylate cyclase 1 (Adcy1), mRNA [NM_009622] KLA 1.07 1.02 1.06 1.07 1.03 1.02 1.01
ATP 1.02 1.04 1.00 .99 .99 .95 .97
KLA/ATP .97 1.05 1.02 1.05 1.01 .98 1.05
Adcy2
KLA  ATP  ATP+KLA
 NM_153534 adenylate cyclase 2 (Adcy2), mRNA [NM_153534] KLA .79 .82 .83 .73 .61 .66 .90
ATP 1.10 1.09 1.02 1.04 .88 .58 .53
KLA/ATP .84 .87 .77 .75 .68 .60 .43
Adcy3
KLA  ATP  ATP+KLA
 NM_138305 adenylate cyclase 3 (Adcy3), mRNA [NM_138305] KLA .84 .84 .83 .78 .66 .55 .49
ATP 1.09 1.05 .89 1.02 .84 .62 1.52
KLA/ATP .93 .87 .75 .85 .66 .83 .77
Adcy4
KLA  ATP  ATP+KLA
 NM_080435 adenylate cyclase 4 (Adcy4), mRNA [NM_080435] KLA 1.05 1.07 .96 1.00 1.04 1.05 1.05
ATP 1.02 1.05 1.02 1.48 1.37 1.08 1.09
KLA/ATP 1.00 1.05 .91 1.19 1.35 1.27 1.08
Adcy5
KLA  ATP  ATP+KLA
 NM_001012765 adenylate cyclase 5 (Adcy5), mRNA [NM_001012765] KLA 1.06 1.00 .97 1.01 1.03 .95 .93
ATP .95 1.08 1.08 1.07 .97 1.03 .97
KLA/ATP .97 .92 1.04 .99 .91 .96 1.04
Adcy6
KLA  ATP  ATP+KLA
 NM_007405 adenylate cyclase 6 (Adcy6), mRNA [NM_007405] KLA 1.10 1.16 1.16 1.09 1.08 1.06 .99
ATP 1.05 .97 1.08 1.12 1.08 1.08 1.04
KLA/ATP 1.14 1.20 1.29 1.30 1.25 1.11 1.07
Adcy7
KLA  ATP  ATP+KLA
 NM_001037724 adenylate cyclase 7 (Adcy7), transcript variant 3, mRNA [NM_001037724] KLA .43 .39 .35 .32 .45 .72 .84
ATP .90 .84 .62 .41 .53 .42 .94
KLA/ATP .39 .34 .23 .17 .41 .34 .67
Adcy7
KLA  ATP  ATP+KLA
 NM_007406 adenylate cyclase 7 (Adcy7), transcript variant 1, mRNA [NM_007406] KLA .51 .52 .48 .41 .59 .81 .99
ATP 1.01 1.02 .62 .52 .53 .38 .98
KLA/ATP .53 .48 .30 .27 .42 .36 .65
Adcy8
KLA  ATP  ATP+KLA
 NM_009623 adenylate cyclase 8 (Adcy8), mRNA [NM_009623] KLA 1.00 1.00 1.07 .97 1.04 .98 1.02
ATP 1.04 1.05 1.14 1.03 .99 1.00 .97
KLA/ATP 1.05 1.04 1.00 1.03 .98 .94 .96
Adcy9
KLA  ATP  ATP+KLA
 NM_009624 adenylate cyclase 9 (Adcy9), mRNA [NM_009624] KLA .18 .15 .13 .15 .17 .19 .33
ATP 1.33 1.16 .97 .98 .62 .56 .86
KLA/ATP .19 .16 .17 .18 .20 .25 .38
AK019932
KLA  ATP  ATP+KLA
 AK019932 adult male pituitary gland cDNA, RIKEN full-length enriched library, clone:5330434N09 product:inferred: transmembrane receptor frizzled 5 {Mus musculus}, full insert sequence [AK019932] KLA .99 .94 .97 .98 .96 .99 1.03
ATP 1.02 1.07 1.02 .97 1.00 .98 .93
KLA/ATP .93 .99 .91 1.04 1.02 1.01 1.00
AK036998
KLA  ATP  ATP+KLA
 AK036998 adult female vagina cDNA, RIKEN full-length enriched library, clone:9930034M05 product:unclassifiable, full insert sequence. [AK036998] KLA 1.43 1.09 .89 .79 .96 .97 .71
ATP 1.04 1.04 .71 .64 .90 .82 .82
KLA/ATP 1.34 1.23 1.01 .89 1.10 .82 .75
AK045358
KLA  ATP  ATP+KLA
 AK045358 adult male corpora quadrigemina cDNA, RIKEN full-length enriched library, clone:B230105H23 product:voltage-dependent anion channel 3, full insert sequence [AK045358] KLA .96 .98 .96 .96 1.02 1.03 1.01
ATP .97 .95 1.01 .99 1.08 1.01 .97
KLA/ATP .99 .99 .98 1.01 .99 1.06 .99
Akt1
KLA  ATP  ATP+KLA
 NM_009652 thymoma viral proto-oncogene 1 (Akt1), mRNA [NM_009652] KLA .80 .80 .75 .75 .71 .70 .82
ATP 1.00 1.02 .76 .85 .76 .68 .84
KLA/ATP .82 .80 .64 .68 .67 .61 .72
Akt2
KLA  ATP  ATP+KLA
 NM_007434 thymoma viral proto-oncogene 2 (Akt2), transcript variant 2, mRNA [NM_007434] KLA 1.45 1.49 1.81 1.61 1.83 1.17 .92
ATP 1.12 1.12 1.00 1.28 1.20 .94 1.06
KLA/ATP 1.48 1.70 1.69 1.58 1.57 1.32 1.27
Akt3
KLA  ATP  ATP+KLA
 NM_011785 thymoma viral proto-oncogene 3 (Akt3), mRNA [NM_011785] KLA 3.42 3.45 5.31 5.16 4.65 3.80 2.12
ATP 1.12 1.22 1.10 1.37 1.02 1.11 1.56
KLA/ATP 3.72 4.17 4.62 4.64 2.74 2.05 3.82
Anapc1
KLA  ATP  ATP+KLA
 AK090134 nullipotent stem cell CRL-2070 NE cDNA, RIKEN full-length enriched library, clone:G431003J08 product:meiotic check point regulator, full insert sequence [AK090134] KLA .79 .76 .72 .64 .56 .54 .76
ATP .99 1.04 1.11 .77 .48 .31 .39
KLA/ATP .72 .75 .73 .57 .42 .30 .25
Anapc1
KLA  ATP  ATP+KLA
 NM_008569 anaphase promoting complex subunit 1 (Anapc1), mRNA [NM_008569] KLA 1.00 .89 .81 .89 .66 .75 .74
ATP .88 .79 .97 .46 .48 .93 .76
KLA/ATP .76 .77 .83 .37 .44 .74 .62
Anapc10
KLA  ATP  ATP+KLA
 NM_026904 anaphase promoting complex subunit 10 (Anapc10), mRNA [NM_026904] KLA 1.38 1.24 1.22 1.30 1.13 1.14 1.05
ATP .96 .99 1.22 1.01 .77 1.16 .94
KLA/ATP 1.19 1.24 1.50 1.23 .97 1.17 1.02
Anapc11
KLA  ATP  ATP+KLA
 NM_001038230 anaphase promoting complex subunit 11 homolog (yeast) (Anapc11), transcript variant 1, mRNA [NM_001038230] KLA .89 .90 .91 .85 .82 .78 .82
ATP 1.01 1.06 1.04 1.06 1.00 .85 .75
KLA/ATP .96 .93 .83 .96 .87 .79 .64
Anapc2
KLA  ATP  ATP+KLA
 NM_175300 anaphase promoting complex subunit 2 (Anapc2), mRNA [NM_175300] KLA .90 .92 1.02 .91 1.03 .94 .81
ATP 1.08 1.16 .96 1.18 .86 .75 .94
KLA/ATP 1.04 1.07 .93 1.11 .84 .66 .89
Anapc4
KLA  ATP  ATP+KLA
 NM_024213 anaphase promoting complex subunit 4 (Anapc4), mRNA [NM_024213] KLA .94 .99 1.01 1.08 1.21 1.22 1.09
ATP .95 .91 .86 .69 .61 .89 .96
KLA/ATP .93 .95 .84 .77 .80 .96 1.00
Anapc5
KLA  ATP  ATP+KLA
 NM_021505 anaphase-promoting complex subunit 5 (Anapc5), transcript variant 1, mRNA [NM_021505] KLA .80 .82 .83 .82 .79 .84 1.10
ATP .99 .99 .89 .81 .79 .70 .71
KLA/ATP .82 .81 .72 .62 .63 .73 .68
Anapc7
KLA  ATP  ATP+KLA
 AK049968 adult male hippocampus cDNA, RIKEN full-length enriched library, clone:C630034H22 product:anaphase-promoting complex subunit 7, full insert sequence. [AK049968] KLA .89 .86 .88 .85 .91 .95 .89
ATP .92 .89 .89 .86 .96 .99 1.00
KLA/ATP .89 .79 .83 .85 .93 .92 .87
Anapc7
KLA  ATP  ATP+KLA
 NM_019805 anaphase promoting complex subunit 7 (Anapc7), mRNA [NM_019805] KLA .65 .69 .70 .79 .91 1.00 .92
ATP .96 .99 .81 .89 1.46 1.30 1.00
KLA/ATP .70 .73 .64 .72 1.14 1.28 1.04
Apc
KLA  ATP  ATP+KLA
 NM_007462 adenomatosis polyposis coli (Apc), mRNA [NM_007462] KLA .98 .94 .91 .86 .83 .91 1.01
ATP 1.06 1.16 1.04 .97 1.63 1.50 1.25
KLA/ATP 1.01 1.01 .92 .88 1.22 1.46 1.21
Apc2
KLA  ATP  ATP+KLA
 NM_011789 adenomatosis polyposis coli 2 (Apc2), mRNA [NM_011789] KLA 1.05 1.15 1.12 1.13 1.07 1.11 1.08
ATP 1.04 .97 1.15 1.27 1.12 1.09 1.16
KLA/ATP 1.12 1.20 1.21 1.24 1.25 1.13 1.04
Atf1
KLA  ATP  ATP+KLA
 NM_007497 activating transcription factor 1 (Atf1), mRNA [NM_007497] KLA .71 .73 .74 .79 .89 1.02 1.27
ATP 1.05 1.14 1.17 1.58 4.22 2.94 1.86
KLA/ATP .75 .78 .77 .90 2.98 3.50 2.39
Atf2
KLA  ATP  ATP+KLA
 AK047405 10 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:B930056P03 product:activating transcription factor 2, full insert sequence. [AK047405] KLA 1.01 1.00 1.02 1.04 1.03 1.03 1.00
ATP .99 1.00 .95 1.01 1.04 .98 1.03
KLA/ATP 1.07 1.00 .98 .99 1.00 1.03 .93
Atf2
KLA  ATP  ATP+KLA
 NM_001025093 activating transcription factor 2 (Atf2), transcript variant 1, mRNA [NM_001025093] KLA 1.35 1.30 1.32 1.31 1.37 1.09 1.20
ATP 1.15 1.17 .99 1.11 1.22 1.39 1.28
KLA/ATP 1.38 1.42 1.21 1.28 1.17 1.33 1.69
Atf3
KLA  ATP  ATP+KLA
 NM_007498 activating transcription factor 3 (Atf3), mRNA [NM_007498] KLA 1.95 2.23 1.99 2.03 1.86 2.12 1.97
ATP 1.15 2.05 4.52 7.49 3.91 1.67 1.74
KLA/ATP 2.02 2.85 3.90 6.24 6.00 3.32 3.79
Atf4
KLA  ATP  ATP+KLA
 NM_009716 activating transcription factor 4 (Atf4), mRNA [NM_009716] KLA .91 1.06 1.13 1.31 1.92 2.59 3.01
ATP 1.05 1.14 1.34 2.88 4.84 2.36 2.56
KLA/ATP 1.14 1.08 1.17 2.40 3.72 3.54 3.62
Atm
KLA  ATP  ATP+KLA
 NM_007499 ataxia telangiectasia mutated homolog (human) (Atm), mRNA [NM_007499] KLA 1.86 1.97 2.17 1.67 1.20 .86 .79
ATP 1.09 1.17 1.01 .97 .61 .63 .69
KLA/ATP 2.11 2.24 1.55 1.46 .85 .75 .59
Bax
KLA  ATP  ATP+KLA
 NM_007527 Bcl2-associated X protein (Bax), mRNA [NM_007527] KLA 1.08 1.14 1.10 1.14 1.17 1.06 .92
ATP 1.06 1.05 1.02 1.25 1.26 .90 .86
KLA/ATP 1.11 1.19 1.30 1.34 1.34 .87 .71
BB113440
KLA  ATP  ATP+KLA
 BB113440 gb|BB113440 RIKEN full-length enriched, adult male urinary bladder Mus musculus cDNA clone 9530041B19 3. [BB113440] KLA .94 .95 .94 .95 1.05 .99 1.05
ATP 1.03 1.07 1.79 1.71 1.51 1.12 1.06
KLA/ATP .95 1.11 1.27 1.15 1.05 1.14 1.25
Bcl2l1
KLA  ATP  ATP+KLA
 NM_009743 Bcl2-like 1 (Bcl2l1), nuclear gene encoding mitochondrial protein, mRNA [NM_009743] KLA .99 1.02 1.10 1.16 1.27 .97 1.05
ATP 1.18 1.42 .81 1.26 1.51 .71 1.67
KLA/ATP 1.21 1.30 .66 1.15 1.31 1.17 1.59
BI646741
KLA  ATP  ATP+KLA
 BI646741 gb|BI646741 603279769F1 NCI_CGAP_Mam3 Mus musculus cDNA clone IMAGE:5320025 5, mRNA sequence [BI646741] KLA .55 .54 .47 .54 .65 1.09 1.60
ATP 1.04 .99 .93 1.08 2.49 .79 .88
KLA/ATP .54 .49 .54 .60 1.21 .97 1.54
Bub1b
KLA  ATP  ATP+KLA
 NM_009773 budding uninhibited by benzimidazoles 1 homolog, beta (S. cerevisiae) (Bub1b), mRNA [NM_009773] KLA .31 .30 .30 .27 .23 .22 .13
ATP 1.10 1.06 1.02 .98 .60 .40 .15
KLA/ATP .35 .30 .32 .41 .32 .25 .15
Bub3
KLA  ATP  ATP+KLA
 AK083742 9 days embryo whole body cDNA, RIKEN full-length enriched library, clone:D030073O17 product:unclassifiable, full insert sequence. [AK083742] KLA .77 .74 .83 .76 .91 .80 .78
ATP 1.02 .74 .70 .69 1.08 1.05 .79
KLA/ATP .65 .65 .70 .72 1.02 .88 .64
Bub3
KLA  ATP  ATP+KLA
 NM_009774 budding uninhibited by benzimidazoles 3 homolog (S. cerevisiae) (Bub3), mRNA [NM_009774] KLA .84 .90 .90 .84 .86 .82 .76
ATP 1.07 1.10 1.04 1.14 .89 .84 .65
KLA/ATP .93 .97 .83 1.00 .80 .78 .48
Calr
KLA  ATP  ATP+KLA
 NM_007591 calreticulin (Calr), mRNA [NM_007591] KLA .86 .95 1.00 .68 .92 .93 1.37
ATP 1.12 1.34 .91 1.33 1.07 .97 1.46
KLA/ATP 1.09 1.02 .63 1.06 .65 .92 1.16
Canx
KLA  ATP  ATP+KLA
 NM_007597 calnexin (Canx), transcript variant 1, mRNA [NM_007597] KLA 1.00 1.01 .92 .87 .85 .86 1.04
ATP 1.00 1.13 .97 1.04 .90 .75 .81
KLA/ATP 1.02 1.10 .82 .90 .63 .55 .60
Ccnb2
KLA  ATP  ATP+KLA
 NM_007630 cyclin B2 (Ccnb2), mRNA [NM_007630] KLA .60 .51 .52 .39 .25 .15 .09
ATP .99 .89 1.32 1.14 .93 .55 .10
KLA/ATP .58 .52 .70 .59 .86 .47 .15
Ccnd1
KLA  ATP  ATP+KLA
 S78355 gb|Cyl-1=cyclin D1 [mice, BALB/c, brain, mRNA, 3737 nt]. [S78355] KLA .24 .23 .23 .24 .29 .47 .17
ATP 1.02 1.02 .88 .80 .52 .10 .21
KLA/ATP .27 .23 .22 .24 .27 .25 .14
Ccnd2
KLA  ATP  ATP+KLA
 NM_009829 cyclin D2 (Ccnd2), mRNA [NM_009829] KLA 12.92 13.66 11.94 12.37 11.11 5.44 1.53
ATP .98 .75 .50 .57 1.24 2.83 .40
KLA/ATP 11.19 11.62 10.34 7.96 7.92 7.10 2.57
Ccnd3
KLA  ATP  ATP+KLA
 NM_007632 cyclin D3 (Ccnd3), transcript variant 1, mRNA [NM_007632] KLA .60 .65 .86 1.02 1.91 2.26 1.45
ATP 1.05 1.14 .89 1.20 .74 .76 .99
KLA/ATP .70 .67 .54 .83 .61 1.19 1.45
Cd3d
KLA  ATP  ATP+KLA
 NM_013487 CD3 antigen, delta polypeptide (Cd3d), mRNA [NM_013487] KLA 1.01 1.05 1.00 .95 .98 1.03 1.02
ATP 1.02 .94 1.08 .99 .99 .94 1.05
KLA/ATP .93 .91 .99 .98 .96 .96 1.04
Cd3e
KLA  ATP  ATP+KLA
 NM_007648 CD3 antigen, epsilon polypeptide (Cd3e), mRNA [NM_007648] KLA 1.21 1.25 1.29 1.22 1.29 1.32 1.13
ATP .98 1.00 1.10 1.11 1.10 1.19 1.11
KLA/ATP 1.24 1.30 1.32 1.30 1.22 1.19 1.10
Cd3g
KLA  ATP  ATP+KLA
 NM_009850 CD3 antigen, gamma polypeptide (Cd3g), mRNA [NM_009850] KLA 1.05 1.01 .96 1.01 1.02 .99 .99
ATP .94 .97 .99 .99 .95 1.02 1.07
KLA/ATP .95 .92 1.08 1.03 1.01 1.01 .99
Cd40
KLA  ATP  ATP+KLA
 NM_170701 CD40 antigen (Cd40), transcript variant 3, mRNA [NM_170701] KLA 23.87 23.62 23.26 23.98 22.07 17.37 5.34
ATP 1.00 1.01 1.06 2.96 2.65 3.03 1.70
KLA/ATP 22.77 23.79 29.67 28.85 28.08 21.62 13.02
Cdc16
KLA  ATP  ATP+KLA
 AK012511 11 days embryo whole body cDNA, RIKEN full-length enriched library, clone:2700071J12 product:unclassifiable, full insert sequence. [AK012511] KLA .97 .92 .89 .90 .93 .92 .99
ATP .97 .94 .89 .92 .89 .94 .91
KLA/ATP .98 .88 .99 .93 .80 .89 .82
Cdc16
KLA  ATP  ATP+KLA
 NM_027276 CDC16 cell division cycle 16 homolog (S. cerevisiae) (Cdc16), mRNA [NM_027276] KLA .96 .98 .97 .90 .89 .85 .88
ATP 1.03 1.02 1.06 .82 .70 .87 .71
KLA/ATP .96 .93 .96 .79 .68 .73 .61
Cdc20
KLA  ATP  ATP+KLA
 NM_023223 cell division cycle 20 homolog (S. cerevisiae) (Cdc20), mRNA [NM_023223] KLA .18 .15 .14 .12 .10 .09 .06
ATP .91 .88 1.33 1.11 .72 .46 .07
KLA/ATP .16 .15 .20 .18 .19 .17 .07
Cdc23
KLA  ATP  ATP+KLA
 NM_178347 CDC23 (cell division cycle 23, yeast, homolog) (Cdc23), mRNA [NM_178347] KLA .74 .76 .75 .74 .72 .79 .79
ATP 1.06 1.04 .91 .71 .48 .60 .71
KLA/ATP .76 .77 .73 .66 .46 .51 .59
Cdc26
KLA  ATP  ATP+KLA
 AK041840 3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630041F01 product:unclassifiable, full insert sequence. [AK041840] KLA .92 .88 .95 .88 1.08 .99 1.15
ATP .72 .64 .61 .75 .91 .85 1.04
KLA/ATP .84 .75 .66 .87 .94 .95 .99
Cdc26
KLA  ATP  ATP+KLA
 NM_139291 cell division cycle 26 (Cdc26), mRNA [NM_139291] KLA 1.04 1.07 1.01 1.25 1.38 1.55 1.25
ATP .98 .97 1.06 .91 .91 1.47 1.38
KLA/ATP .88 1.02 1.24 .99 1.25 1.66 1.74
Cdc27
KLA  ATP  ATP+KLA
 NM_145436 cell division cycle 27 homolog (S. cerevisiae) (Cdc27), mRNA [NM_145436] KLA 1.36 1.25 1.22 1.07 1.05 1.06 1.00
ATP .90 .97 1.06 .84 .81 .88 .73
KLA/ATP 1.25 1.22 1.07 .87 .98 .95 .72
Cdk4
KLA  ATP  ATP+KLA
 NM_009870 cyclin-dependent kinase 4 (Cdk4), mRNA [NM_009870] KLA .66 .72 .65 .55 .46 .50 .71
ATP 1.03 1.02 .53 .65 .66 .63 .75
KLA/ATP .78 .61 .31 .42 .44 .62 .43
Cdkn1a
KLA  ATP  ATP+KLA
 NM_007669 cyclin-dependent kinase inhibitor 1A (P21) (Cdkn1a), transcript variant 1, mRNA [NM_007669] KLA 4.72 4.90 4.96 3.73 2.11 1.14 1.02
ATP 1.14 1.52 .95 1.69 1.47 2.21 .50
KLA/ATP 5.99 7.08 3.86 6.37 3.00 2.55 2.05
Cdkn2a
KLA  ATP  ATP+KLA
 NM_009877 cyclin-dependent kinase inhibitor 2A (Cdkn2a), transcript variant 1, mRNA [NM_009877] KLA .95 .95 .86 .96 .91 .90 .75
ATP 1.00 .99 .95 .95 .97 .89 .77
KLA/ATP .95 .96 .92 .94 .90 .85 .76
Cdkn2b
KLA  ATP  ATP+KLA
 NM_007670 cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) (Cdkn2b), mRNA [NM_007670] KLA .70 .75 .94 1.44 1.66 .55 .81
ATP 1.02 .89 1.00 .86 1.33 3.87 .57
KLA/ATP .71 .77 .91 .94 .74 1.64 1.17
Cdkn2c
KLA  ATP  ATP+KLA
 NM_007671 cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) (Cdkn2c), mRNA [NM_007671] KLA .32 .29 .29 .27 .20 .20 .15
ATP .88 .87 .62 .52 .49 .39 .23
KLA/ATP .30 .29 .30 .34 .34 .34 .20
Cdkn2c
KLA  ATP  ATP+KLA
 U19596 Cdk4 and Cdk6 inhibitor p18 protein mRNA, complete cds. [U19596] KLA .32 .32 .30 .27 .21 .20 .15
ATP .91 .90 .57 .52 .49 .40 .22
KLA/ATP .35 .31 .29 .36 .35 .35 .20
Chek1
KLA  ATP  ATP+KLA
 NM_007691 checkpoint kinase 1 homolog (S. pombe) (Chek1), mRNA [NM_007691] KLA .36 .35 .37 .36 .34 .44 .31
ATP 1.12 1.14 1.17 1.08 .64 .43 .32
KLA/ATP .37 .36 .48 .46 .49 .36 .25
Chek2
KLA  ATP  ATP+KLA
 NM_016681 CHK2 checkpoint homolog (S. pombe) (Chek2), mRNA [NM_016681] KLA .55 .54 .46 .55 .47 .52 .59
ATP 1.07 1.10 .83 .88 .64 .61 .62
KLA/ATP .54 .51 .49 .55 .56 .57 .46
Chuk
KLA  ATP  ATP+KLA
 NM_007700 conserved helix-loop-helix ubiquitous kinase (Chuk), mRNA [NM_007700] KLA 1.32 1.42 1.41 1.17 1.32 1.22 1.40
ATP 1.22 1.30 1.18 .97 1.02 1.00 1.37
KLA/ATP 1.56 1.61 1.21 1.09 .83 .84 1.17
Creb1
KLA  ATP  ATP+KLA
 NM_009952 cAMP responsive element binding protein 1 (Creb1), transcript variant B, mRNA [NM_009952] KLA 1.42 1.33 1.16 .99 .83 .97 .92
ATP .92 .91 1.18 1.38 1.51 1.02 .75
KLA/ATP 1.34 1.31 1.49 1.37 1.71 1.05 .93
Crebbp
KLA  ATP  ATP+KLA
 AK048818 0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230072N21 product:hypothetical protein, full insert sequence [AK048818] KLA 1.44 1.19 1.26 1.25 1.25 1.36 1.24
ATP .98 .90 1.04 1.11 1.95 2.72 1.51
KLA/ATP 1.17 1.27 1.45 1.28 1.98 2.80 2.52
Crebbp
KLA  ATP  ATP+KLA
 NM_001025432 CREB binding protein (Crebbp), mRNA [NM_001025432] KLA .97 1.01 .98 1.06 1.05 .99 1.07
ATP 1.07 1.05 .96 1.01 1.15 1.14 1.00
KLA/ATP 1.01 .97 .97 1.00 1.03 1.23 1.13
Crebbp
KLA  ATP  ATP+KLA
 S66385 gb|CREB-binding protein [mice, brain, mRNA Partial, 7326 nt]. [S66385] KLA 1.00 .98 1.08 .98 1.04 1.07 1.08
ATP .99 .98 .99 1.09 1.13 1.08 1.05
KLA/ATP 1.06 1.00 1.05 1.03 1.02 1.14 1.11
Crem
KLA  ATP  ATP+KLA
 NM_013498 cAMP responsive element modulator (Crem), transcript variant 3, mRNA [NM_013498] KLA 1.85 2.02 2.58 2.17 1.59 1.31 .79
ATP 1.04 1.44 4.98 5.47 6.53 9.31 2.55
KLA/ATP 1.84 2.15 4.41 4.79 7.98 10.80 4.25
Crtc2
KLA  ATP  ATP+KLA
 NM_028881 CREB regulated transcription coactivator 2 (Crtc2), mRNA [NM_028881] KLA 1.86 1.66 1.48 1.25 1.49 1.36 1.51
ATP 1.21 1.19 1.14 2.17 2.30 1.65 1.39
KLA/ATP 1.98 1.95 1.74 2.87 2.33 1.79 2.04
Crtc3
KLA  ATP  ATP+KLA
 NM_173863 CREB regulated transcription coactivator 3 (Crtc3), mRNA [NM_173863] KLA .83 .94 .88 .94 1.00 1.06 1.05
ATP 1.11 1.12 1.11 1.27 1.34 1.27 1.15
KLA/ATP .95 .94 .99 1.00 1.26 1.47 1.45
Csf2
KLA  ATP  ATP+KLA
 NM_009969 colony stimulating factor 2 (granulocyte-macrophage) (Csf2), mRNA [NM_009969] KLA 1.44 1.53 1.38 1.37 1.15 1.21 1.14
ATP 1.01 1.02 1.85 9.73 2.64 1.90 1.14
KLA/ATP 1.49 1.84 2.14 2.80 1.67 1.36 1.35
Ctnnb1
KLA  ATP  ATP+KLA
 AK020013 adult male thymus cDNA, RIKEN full-length enriched library, clone:5830416C23 product:catenin beta, full insert sequence. [AK020013] KLA 1.06 1.15 1.00 1.06 1.27 1.14 1.03
ATP .85 .57 1.74 3.36 4.13 2.19 1.55
KLA/ATP 1.12 .87 2.47 3.61 3.79 2.21 2.06
Ctnnb1
KLA  ATP  ATP+KLA
 NM_007614 catenin (cadherin associated protein), beta 1 (Ctnnb1), mRNA [NM_007614] KLA 1.02 1.07 1.13 1.03 1.04 .93 .96
ATP 1.12 1.14 .75 .77 .73 .72 1.52
KLA/ATP 1.18 1.17 .77 .85 .60 .59 1.35
Dlg1
KLA  ATP  ATP+KLA
 AK031364 13 days embryo male testis cDNA, RIKEN full-length enriched library, clone:6030413K05 product:discs, large homolog 1 (Drosophila), full insert sequence. [AK031364] KLA .92 .85 .88 .82 .95 .91 .98
ATP 1.11 1.01 .90 .87 1.03 .93 .92
KLA/ATP .94 .93 .80 .81 1.01 .90 .87
Dlg1
KLA  ATP  ATP+KLA
 NM_007862 discs, large homolog 1 (Drosophila) (Dlg1), mRNA [NM_007862] KLA 1.17 1.11 1.13 1.05 .89 .91 1.05
ATP .98 .97 1.13 1.12 .90 .96 .91
KLA/ATP 1.24 1.11 1.14 1.02 .80 .83 .80
Dvl1
KLA  ATP  ATP+KLA
 NM_010091 dishevelled, dsh homolog 1 (Drosophila) (Dvl1), mRNA [NM_010091] KLA .93 .91 .86 .74 .70 .80 1.05
ATP 1.01 1.01 .91 .91 .98 1.10 1.02
KLA/ATP 1.00 .93 .79 .82 .81 .85 1.06
Dvl2
KLA  ATP  ATP+KLA
 NM_007888 dishevelled 2, dsh homolog (Drosophila) (Dvl2), mRNA [NM_007888] KLA .49 .52 .48 .53 .52 .67 .75
ATP 1.08 1.08 .76 .93 1.47 .89 1.20
KLA/ATP .57 .47 .40 .61 1.37 .91 .92
Dvl3
KLA  ATP  ATP+KLA
 NM_007889 dishevelled 3, dsh homolog (Drosophila) (Dvl3), mRNA [NM_007889] KLA 1.08 1.09 1.05 1.18 1.11 1.10 1.11
ATP 1.00 1.01 1.05 1.05 .99 1.10 1.15
KLA/ATP 1.12 1.07 1.09 1.09 1.06 1.15 1.09
E2f1
KLA  ATP  ATP+KLA
 NM_007891 E2F transcription factor 1 (E2f1), mRNA [NM_007891] KLA .41 .44 .42 .41 .48 .77 .90
ATP 1.01 1.09 1.04 1.13 .83 .53 .84
KLA/ATP .44 .44 .52 .50 .49 .46 .85
E2f2
KLA  ATP  ATP+KLA
 NM_177733 E2F transcription factor 2 (E2f2), mRNA [NM_177733] KLA .13 .13 .14 .20 .19 .19 .18
ATP 1.08 .92 1.01 .85 .65 .38 .38
KLA/ATP .13 .13 .21 .20 .32 .24 .26
E2f3
KLA  ATP  ATP+KLA
 AK085296 0 day neonate kidney cDNA, RIKEN full-length enriched library, clone:D630007K21 product:E2F transcription factor 3, full insert sequence. [AK085296] KLA .98 .97 1.02 1.00 .99 .99 .99
ATP .97 1.06 1.03 .98 1.01 .99 1.00
KLA/ATP 1.12 1.14 1.03 .99 .96 .93 .96
E2f3
KLA  ATP  ATP+KLA
 NM_010093 E2F transcription factor 3 (E2f3), mRNA [NM_010093] KLA 1.11 1.09 1.13 1.21 1.47 1.62 1.65
ATP .97 .98 1.08 1.15 1.45 1.73 1.80
KLA/ATP 1.21 1.13 1.07 1.20 1.45 1.56 1.62
Egr1
KLA  ATP  ATP+KLA
 NM_007913 early growth response 1 (Egr1), mRNA [NM_007913] KLA 1.00 .56 1.72 2.17 1.88 1.59 2.89
ATP 8.02 5.01 71.67 137.15 83.52 19.89 1.19
KLA/ATP 8.95 15.55 146.78 187.64 170.49 44.28 3.89
Egr2
KLA  ATP  ATP+KLA
 NM_010118 early growth response 2 (Egr2), mRNA [NM_010118] KLA .20 .24 .23 .28 .25 .15 .08
ATP 4.23 6.98 16.71 19.88 4.99 1.41 1.59
KLA/ATP 1.38 4.50 10.98 12.78 3.75 .37 .22
Elk1
KLA  ATP  ATP+KLA
 AK082260 0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230030F12 product:ELK1, member of ETS oncogene family, full insert sequence. [AK082260] KLA 1.02 1.01 1.01 .97 1.00 1.03 1.06
ATP 1.02 1.07 1.06 1.03 1.02 1.02 1.00
KLA/ATP 1.08 .99 .97 1.01 1.02 1.06 .95
Elk4
KLA  ATP  ATP+KLA
 AK037559 16 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A130026I01 product:unclassifiable, full insert sequence. [AK037559] KLA 1.04 .93 .96 .94 .99 1.06 .93
ATP .95 .98 .89 .92 .96 1.00 .96
KLA/ATP .94 .94 .99 .92 .93 .99 .96
Elk4
KLA  ATP  ATP+KLA
 NM_007923 ELK4, member of ETS oncogene family (Elk4), mRNA [NM_007923] KLA .96 1.04 1.07 1.04 1.05 1.01 1.09
ATP .93 1.01 1.02 1.01 1.00 1.10 1.01
KLA/ATP .98 1.01 .94 1.02 1.03 1.04 1.04
Ep300
KLA  ATP  ATP+KLA
 AK042627 7 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:A730011L11 product:P300 TRANSCRIPTION COACTIVATOR (FRAGMENT) homolog [Mus sp], full insert sequence. [AK042627] KLA 1.02 .95 .92 1.04 1.01 1.00 1.05
ATP 1.06 .89 .88 .89 1.00 .90 1.07
KLA/ATP 1.10 1.02 .87 .91 1.04 .97 .98
Ep300
KLA  ATP  ATP+KLA
 NM_177821 E1A binding protein p300 (Ep300), mRNA [NM_177821] KLA 1.61 1.26 1.57 1.38 1.78 1.41 1.40
ATP 1.34 1.60 1.11 1.08 1.16 1.05 1.15
KLA/ATP 1.86 1.94 1.18 1.56 1.71 1.42 2.05
Ets1
KLA  ATP  ATP+KLA
 NM_011808 E26 avian leukemia oncogene 1, 5 domain (Ets1), transcript variant 1, mRNA [NM_011808] KLA .55 .54 .49 .66 .62 .58 .67
ATP 1.01 1.14 .98 1.11 1.59 1.48 .67
KLA/ATP .58 .53 .58 .70 .80 .76 .76
Ets1
KLA  ATP  ATP+KLA
 X55787 gb|M.musculus c-ets-1 gene. [X55787] KLA .83 .93 .85 .89 .94 .90 1.03
ATP 1.08 1.11 .92 1.04 1.19 1.19 .98
KLA/ATP .94 .90 .88 .98 .91 .92 .95
Ets2
KLA  ATP  ATP+KLA
 NM_011809 E26 avian leukemia oncogene 2, 3 domain (Ets2), mRNA [NM_011809] KLA .79 .82 1.09 1.44 1.83 1.08 1.46
ATP 1.23 1.59 1.97 3.69 7.13 4.30 .90
KLA/ATP .84 1.33 2.37 5.17 6.58 5.50 3.04
Fdps
KLA  ATP  ATP+KLA
 AK077979 13 days embryo male testis cDNA, RIKEN full-length enriched library, clone:6030492I17 product:farnesyl diphosphate synthetase, full insert sequence. [AK077979] KLA .76 .79 .79 .69 .65 .37 .49
ATP .63 .70 .85 .30 .46 .89 .86
KLA/ATP .54 .52 .63 .39 .42 .40 .31
Fdps
KLA  ATP  ATP+KLA
 NM_134469 farnesyl diphosphate synthetase (Fdps), mRNA [NM_134469] KLA .87 .93 .89 .97 .76 .43 .48
ATP 1.12 1.10 1.05 1.23 1.05 .60 .88
KLA/ATP .93 .99 1.00 1.02 .70 .45 .33
Fos
KLA  ATP  ATP+KLA
 NM_010234 FBJ osteosarcoma oncogene (Fos), mRNA [NM_010234] KLA .42 .33 .64 .61 .71 .85 .71
ATP 3.48 5.46 23.78 25.22 1.71 2.36 1.50
KLA/ATP .90 1.74 5.97 8.62 1.28 2.42 4.52
Fosl1
KLA  ATP  ATP+KLA
 NM_010235 fos-like antigen 1 (Fosl1), mRNA [NM_010235] KLA .75 .72 .50 .55 .87 .97 1.29
ATP 1.00 .99 .72 1.57 7.76 9.10 2.11
KLA/ATP .83 .75 .53 .65 1.53 3.70 3.26
Fzd1
KLA  ATP  ATP+KLA
 NM_021457 frizzled homolog 1 (Drosophila) (Fzd1), mRNA [NM_021457] KLA 15.53 16.47 14.36 11.40 6.80 2.73 2.49
ATP 1.01 1.02 1.39 2.05 6.43 10.47 1.41
KLA/ATP 12.71 14.30 14.99 14.06 9.72 9.90 8.10
Fzd10
KLA  ATP  ATP+KLA
 NM_175284 frizzled homolog 10 (Drosophila) (Fzd10), mRNA [NM_175284] KLA .99 .98 .99 1.03 1.03 1.02 .99
ATP .98 .98 .97 1.03 1.05 1.00 .96
KLA/ATP .96 .98 1.08 1.02 1.04 1.02 1.00
Fzd2
KLA  ATP  ATP+KLA
 NM_020510 frizzled homolog 2 (Drosophila) (Fzd2), mRNA [NM_020510] KLA .97 1.01 1.01 1.02 1.00 .96 .97
ATP 1.01 1.02 1.03 1.02 .97 1.03 .93
KLA/ATP 1.04 .98 .99 1.03 .99 1.03 .98
Fzd3
KLA  ATP  ATP+KLA
 NM_021458 frizzled homolog 3 (Drosophila) (Fzd3), mRNA [NM_021458] KLA 1.00 1.00 .99 1.04 1.02 1.06 1.07
ATP 1.00 1.00 .95 1.04 1.04 1.01 1.05
KLA/ATP .98 1.05 1.06 .99 1.02 1.00 1.03
Fzd4
KLA  ATP  ATP+KLA
 NM_008055 frizzled homolog 4 (Drosophila) (Fzd4), mRNA [NM_008055] KLA .96 .88 .91 .92 .82 .89 .84
ATP .97 .98 1.05 1.02 .93 .90 .96
KLA/ATP .82 .86 .97 .92 .88 .91 .92
Fzd5
KLA  ATP  ATP+KLA
 NM_022721 frizzled homolog 5 (Drosophila) (Fzd5), transcript variant 1, mRNA [NM_022721] KLA 1.63 1.69 1.56 1.23 .91 1.01 .92
ATP 1.03 1.32 4.46 9.23 7.72 2.14 1.11
KLA/ATP 1.63 1.92 4.20 8.67 8.29 3.07 1.12
Fzd6
KLA  ATP  ATP+KLA
 NM_008056 frizzled homolog 6 (Drosophila) (Fzd6), mRNA [NM_008056] KLA .97 1.01 .96 .90 .87 .94 .98
ATP .98 .97 .98 .94 .95 1.09 .96
KLA/ATP .97 1.02 .94 .92 .90 1.02 1.00
Fzd7
KLA  ATP  ATP+KLA
 NM_008057 frizzled homolog 7 (Drosophila) (Fzd7), mRNA [NM_008057] KLA 1.50 1.68 1.53 1.31 1.13 1.00 .94
ATP 1.04 1.12 1.60 3.45 2.56 1.72 1.02
KLA/ATP 1.89 1.92 1.96 4.61 3.75 3.38 1.88
Fzd8
KLA  ATP  ATP+KLA
 AK034561 12 days embryo embryonic body between diaphragm region and neck cDNA, RIKEN full-length enriched library, clone:9430006K02 product:inferred: transmembrane receptor {Mus musculus}; frizzled homolog 8 (Drosophila) homolog {GNF expression}, KLA 1.00 .98 1.05 .98 .96 1.03 .94
ATP 1.00 .92 1.06 1.05 1.02 1.01 .98
KLA/ATP .99 1.06 .99 .94 .95 .99 1.03
Fzd8
KLA  ATP  ATP+KLA
 NM_008058 frizzled homolog 8 (Drosophila) (Fzd8), mRNA [NM_008058] KLA 1.09 1.15 1.07 1.05 1.03 1.05 .98
ATP 1.05 1.08 2.01 3.38 2.89 1.20 1.03
KLA/ATP 1.04 1.17 1.65 2.57 2.62 1.40 1.04
Fzd9
KLA  ATP  ATP+KLA
 NM_010246 frizzled homolog 9 (Drosophila) (Fzd9), mRNA [NM_010246] KLA 1.03 1.10 1.12 .96 .98 1.00 .94
ATP 1.00 1.00 1.03 1.06 1.07 1.14 .98
KLA/ATP 1.10 1.07 1.03 .84 1.11 .96 .98
Gcn5l2
KLA  ATP  ATP+KLA
 NM_020004 GCN5 general control of amino acid synthesis-like 2 (yeast) (Gcn5l2), transcript variant 1, mRNA [NM_020004] KLA .86 .86 .77 .82 .91 .97 1.10
ATP 1.13 1.27 1.06 1.44 .73 .63 .90
KLA/ATP 1.02 1.05 .82 1.05 .54 .62 .69
Gps2
KLA  ATP  ATP+KLA
 NM_019726 G protein pathway suppressor 2 (Gps2), mRNA [NM_019726] KLA .82 .88 .84 .92 1.18 .96 1.15
ATP 1.17 1.28 .91 1.87 1.20 .70 1.03
KLA/ATP .96 1.02 .63 1.26 .81 .83 1.12
Gsk3b
KLA  ATP  ATP+KLA
 NM_019827 glycogen synthase kinase 3 beta (Gsk3b), mRNA [NM_019827] KLA 1.06 1.03 1.11 1.01 1.26 1.28 1.26
ATP 1.18 1.27 1.15 2.07 2.37 2.32 1.67
KLA/ATP 1.15 1.21 .98 1.50 1.67 2.50 2.99
H2-Aa
KLA  ATP  ATP+KLA
 NM_010378 histocompatibility 2, class II antigen A, alpha (H2-Aa), mRNA [NM_010378] KLA 1.43 1.59 1.68 1.50 1.62 1.89 1.64
ATP 1.07 1.15 1.27 1.90 1.92 1.77 1.55
KLA/ATP 1.62 1.81 1.74 2.29 1.89 1.92 2.19
H2-Ab1
KLA  ATP  ATP+KLA
 BC010322 histocompatibility 2, class II antigen A, beta 1, mRNA (cDNA clone MGC:6297 IMAGE:2651058), complete cds [BC010322] KLA 1.73 1.76 1.77 1.55 1.95 2.10 2.27
ATP 1.03 1.18 1.32 1.99 1.79 1.56 1.61
KLA/ATP 1.70 2.01 1.74 2.52 1.58 2.01 2.75
H2-Ab1
KLA  ATP  ATP+KLA
 NM_207105 histocompatibility 2, class II antigen A, beta 1 (H2-Ab1), mRNA [NM_207105] KLA 2.02 2.15 2.07 2.09 2.32 2.78 3.08
ATP 1.11 1.20 1.42 2.33 2.33 2.25 1.87
KLA/ATP 2.11 2.32 2.52 3.62 2.67 2.96 5.04
H2-Bl
KLA  ATP  ATP+KLA
 NM_008199 histocompatibility 2, blastocyst (H2-Bl), mRNA [NM_008199] KLA 1.29 1.32 1.40 1.28 1.36 1.46 1.80
ATP 1.04 1.11 1.02 1.34 1.28 1.32 1.47
KLA/ATP 1.32 1.39 1.34 1.77 1.41 1.61 2.39
H2-D1
KLA  ATP  ATP+KLA
 AK169750 2 days neonate thymus thymic cells cDNA, RIKEN full-length enriched library, clone:E430019E13 product:histocompatibility 2, D region locus 1, full insert sequence [AK169750] KLA .99 .98 .96 .99 .93 .91 .94
ATP .96 1.01 1.02 .95 1.05 1.00 .98
KLA/ATP .92 .94 .97 .97 .98 .92 1.03
H2-D1
KLA  ATP  ATP+KLA
 NM_010380 histocompatibility 2, D region locus 1 (H2-D1), mRNA [NM_010380] KLA 1.38 1.45 1.73 1.42 1.70 1.76 2.56
ATP 1.15 1.11 .86 1.12 1.19 1.28 1.90
KLA/ATP 1.58 1.72 1.38 1.56 1.38 1.69 3.21
H2-DMa
KLA  ATP  ATP+KLA
 NM_010386 histocompatibility 2, class II, locus DMa (H2-DMa), mRNA [NM_010386] KLA 1.49 1.50 1.65 1.65 1.91 2.23 1.69
ATP 1.04 1.12 1.26 1.67 1.24 .99 1.32
KLA/ATP 1.58 1.68 1.70 2.02 1.37 1.35 1.90
H2-DMb1
KLA  ATP  ATP+KLA
 NM_010387 histocompatibility 2, class II, locus Mb1 (H2-DMb1), mRNA [NM_010387] KLA 1.06 1.14 1.08 1.13 1.24 1.41 1.37
ATP 1.01 1.02 1.09 1.14 .92 .73 1.36
KLA/ATP 1.13 1.05 1.21 1.17 .98 .83 1.41
H2-DMb2
KLA  ATP  ATP+KLA
 NM_010388 histocompatibility 2, class II, locus Mb2 (H2-DMb2), mRNA [NM_010388] KLA 1.00 1.04 .93 .95 .96 .95 1.03
ATP 1.06 1.04 .94 .92 .97 .95 1.00
KLA/ATP .90 .94 .99 .94 .90 .96 .92
H2-Eb1
KLA  ATP  ATP+KLA
 X52641 gb|Mouse mRNA for I-A beta NOD. [X52641] KLA 1.94 2.06 1.94 1.87 1.96 2.18 1.76
ATP 1.11 1.20 1.53 2.70 3.02 2.91 1.40
KLA/ATP 2.09 2.11 2.26 3.55 2.76 3.05 3.05
H2-K1
KLA  ATP  ATP+KLA
 M69070 mRNA, complete cds. [M69070] KLA 1.76 1.66 1.78 1.78 1.87 2.23 2.99
ATP .98 .97 1.19 1.45 1.36 1.68 2.17
KLA/ATP 1.68 1.70 1.87 1.96 1.87 2.13 3.82
H2-K1
KLA  ATP  ATP+KLA
 NM_001001892 histocompatibility 2, K1, K region (H2-K1), transcript variant 1, mRNA [NM_001001892] KLA 1.82 1.66 1.73 1.76 1.87 2.29 3.17
ATP .98 .97 1.13 1.32 1.29 1.57 2.09
KLA/ATP 1.64 1.71 1.77 1.82 1.71 2.12 3.91
H2-M1
KLA  ATP  ATP+KLA
 NM_177636 histocompatibility 2, M region locus 1 (H2-M1), mRNA [NM_177636] KLA .99 1.01 1.02 1.02 .97 1.03 1.04
ATP 1.01 .99 1.03 1.07 .92 1.03 .98
KLA/ATP 1.08 .97 .94 1.04 1.00 1.04 1.02
H2-M10.1
KLA  ATP  ATP+KLA
 NM_013544 histocompatibility 2, M region locus 10.1 (H2-M10.1), mRNA [NM_013544] KLA 1.04 1.00 1.05 .95 .98 1.04 .94
ATP 1.06 1.04 .96 .95 .97 .98 .98
KLA/ATP 1.02 1.07 .98 1.02 .92 .92 .99
H2-M10.2
KLA  ATP  ATP+KLA
 NM_177923 histocompatibility 2, M region locus 10.2 (H2-M10.2), mRNA [NM_177923] KLA 2.18 2.23 2.51 2.61 2.90 3.30 3.40
ATP 1.08 1.02 1.22 1.39 1.30 1.56 2.66
KLA/ATP 2.23 2.53 2.82 2.91 2.89 2.60 3.92
H2-M10.3
KLA  ATP  ATP+KLA
 AY211080 major histocompatibility complex class Ib M10.3 mRNA, complete cds [AY211080] KLA .95 1.08 .99 .95 1.00 1.11 1.04
ATP .98 .96 1.00 .99 1.00 .99 1.00
KLA/ATP 1.00 .99 1.00 1.00 .99 .96 1.03
H2-M10.4
KLA  ATP  ATP+KLA
 NM_177634 histocompatibility 2, M region locus 10.4 (H2-M10.4), mRNA [NM_177634] KLA 1.03 1.04 1.08 1.08 1.04 1.03 1.03
ATP 1.07 1.05 .97 1.08 .95 .97 1.02
KLA/ATP 1.02 .97 1.02 .99 .93 1.06 1.04
H2-M10.5
KLA  ATP  ATP+KLA
 NM_177637 histocompatibility 2, M region locus 10.5 (H2-M10.5), mRNA [NM_177637] KLA 1.00 1.04 1.13 .93 .99 1.00 1.07
ATP 1.02 1.02 1.04 .90 1.03 .99 .99
KLA/ATP 1.06 1.03 .97 1.03 1.03 .98 1.04
H2-M10.6
KLA  ATP  ATP+KLA
 NM_201611 histocompatibility 2, M region locus 10.6 (H2-M10.6), mRNA [NM_201611] KLA 1.06 .99 1.04 1.06 .98 1.03 .92
ATP 1.04 1.09 .96 .98 .94 1.07 .98
KLA/ATP 1.01 1.06 1.02 .96 .96 1.04 1.05
H2-M11
KLA  ATP  ATP+KLA
 NM_177635 histocompatibility 2, M region locus 11 (H2-M11), mRNA [NM_177635] KLA 1.03 1.07 1.06 1.02 .96 1.05 1.03
ATP 1.02 .96 1.08 .98 1.04 .94 .98
KLA/ATP 1.03 1.03 .99 1.01 1.01 .98 .99
H2-M3
KLA  ATP  ATP+KLA
 NM_013819 histocompatibility 2, M region locus 3 (H2-M3), mRNA [NM_013819] KLA 1.90 2.04 2.09 2.37 2.30 2.56 2.73
ATP 1.00 1.00 1.19 1.34 1.00 .70 1.09
KLA/ATP 1.77 1.94 2.37 2.49 1.89 1.67 2.06
H2-M9
KLA  ATP  ATP+KLA
 NM_008205 histocompatibility 2, M region locus 9 (H2-M9), mRNA [NM_008205] KLA 1.03 .99 .96 .98 1.01 .99 1.03
ATP .96 1.06 .94 .96 1.05 1.06 1.00
KLA/ATP .96 1.01 1.01 .99 .97 .95 .98
H2-Oa
KLA  ATP  ATP+KLA
 NM_008206 histocompatibility 2, O region alpha locus (H2-Oa), mRNA [NM_008206] KLA 1.22 1.32 1.37 1.33 1.31 1.26 1.53
ATP 1.02 1.05 1.16 1.21 1.12 1.07 1.16
KLA/ATP 1.32 1.34 1.31 1.34 1.25 1.35 2.78
H2-Ob
KLA  ATP  ATP+KLA
 NM_010389 histocompatibility 2, O region beta locus (H2-Ob), mRNA [NM_010389] KLA 1.05 1.07 1.01 .96 1.10 1.02 1.00
ATP 1.04 .99 1.00 1.03 .94 1.07 .94
KLA/ATP 1.02 .97 1.06 1.08 1.00 .96 1.05
H2-Q1
KLA  ATP  ATP+KLA
 NM_010390 histocompatibility 2, Q region locus 1 (H2-Q1), mRNA [NM_010390] KLA 1.05 1.08 1.03 1.02 .98 1.09 1.00
ATP .99 .92 .93 1.01 1.01 1.04 1.00
KLA/ATP 1.07 1.00 1.00 .91 .97 1.07 1.04
H2-Q10
KLA  ATP  ATP+KLA
 NM_010391 histocompatibility 2, Q region locus 10 (H2-Q10), mRNA [NM_010391] KLA 1.50 1.50 1.70 1.64 1.67 1.79 2.18
ATP 1.12 1.11 1.09 1.46 1.42 1.43 1.69
KLA/ATP 1.61 1.72 1.79 1.94 1.81 1.81 2.93
H2-Q2
KLA  ATP  ATP+KLA
 NM_010392 histocompatibility 2, Q region locus 2 (H2-Q2), mRNA [NM_010392] KLA 1.55 1.52 1.61 1.45 1.83 1.94 2.47
ATP 1.09 1.13 .92 1.16 1.17 1.30 1.88
KLA/ATP 1.55 1.70 1.58 1.80 1.64 1.87 3.43
H2-Q7
KLA  ATP  ATP+KLA
 NM_010394 histocompatibility 2, Q region locus 7 (H2-Q7), mRNA [NM_010394] KLA 1.57 1.58 1.74 1.55 1.82 2.00 2.76
ATP 1.05 1.09 .84 1.12 1.12 1.23 2.00
KLA/ATP 1.63 1.75 1.43 1.67 1.53 1.80 3.48
H2-Q8
KLA  ATP  ATP+KLA
 NM_023124 histocompatibility 2, Q region locus 8 (H2-Q8), mRNA [NM_023124] KLA 7.48 6.46 6.41 7.15 7.46 9.60 18.27
ATP 1.01 .98 1.48 2.05 1.93 3.83 8.26
KLA/ATP 6.72 7.10 9.11 10.95 10.71 12.88 31.43
H2-T22
KLA  ATP  ATP+KLA
 NM_010397 histocompatibility 2, T region locus 22 (H2-T22), mRNA [NM_010397] KLA 5.21 5.40 5.81 6.31 7.42 9.49 7.50
ATP 1.01 .95 .88 .92 .93 3.65 5.53
KLA/ATP 4.83 5.12 4.58 4.74 4.81 6.89 14.89
H2-T23
KLA  ATP  ATP+KLA
 NM_010398 histocompatibility 2, T region locus 23 (H2-T23), mRNA [NM_010398] KLA 1.83 1.80 1.92 1.86 2.32 2.56 3.43
ATP 1.03 1.08 .85 1.18 1.09 1.30 2.49
KLA/ATP 1.76 1.92 1.62 1.93 1.76 2.13 4.06
H2-T24
KLA  ATP  ATP+KLA
 NM_008207 histocompatibility 2, T region locus 24 (H2-T24), mRNA [NM_008207] KLA 3.02 3.26 4.14 4.26 5.15 6.06 5.89
ATP 1.08 1.09 1.32 1.35 1.17 1.71 6.71
KLA/ATP 3.23 3.31 3.54 3.85 3.07 3.73 9.10
H2-T3
KLA  ATP  ATP+KLA
 NM_008208 histocompatibility 2, T region locus 3 (H2-T3), mRNA [NM_008208] KLA .95 1.04 1.00 .97 .97 .99 1.00
ATP .98 1.08 1.03 1.01 .98 1.02 1.03
KLA/ATP 1.05 .96 1.02 1.04 1.05 1.00 .97
Hras1
KLA  ATP  ATP+KLA
 NM_008284 Harvey rat sarcoma virus oncogene 1 (Hras1), mRNA [NM_008284] KLA .79 .82 .77 .82 .94 1.03 1.07
ATP 1.01 .95 .69 .83 .79 1.12 1.15
KLA/ATP .84 .77 .61 .65 .82 1.00 1.05
Htatip
KLA  ATP  ATP+KLA
 NM_178637 HIV-1 tat interactive protein, homolog (human) (Htatip), mRNA [NM_178637] KLA 1.26 1.40 1.45 1.41 1.52 1.29 1.26
ATP .97 .96 .91 1.18 1.32 1.39 1.31
KLA/ATP 1.29 1.32 1.33 1.48 1.54 1.79 1.80
Icam1
KLA  ATP  ATP+KLA
 BC008626 intercellular adhesion molecule, mRNA (cDNA clone MGC:6195 IMAGE:3588949), complete cds [BC008626] KLA 36.67 32.93 28.63 27.91 14.65 8.16 4.15
ATP .96 .88 1.50 3.88 4.98 3.90 1.01
KLA/ATP 32.58 31.60 42.74 32.60 26.00 13.02 6.01
Icam1
KLA  ATP  ATP+KLA
 NM_010493 intercellular adhesion molecule 1 (Icam1), mRNA [NM_010493] KLA 15.66 15.20 12.96 12.31 9.39 6.17 3.81
ATP .96 1.06 1.21 4.19 4.33 3.16 1.06
KLA/ATP 14.31 15.46 17.84 17.60 13.77 8.36 5.42
Ikbkb
KLA  ATP  ATP+KLA
 NM_010546 inhibitor of kappaB kinase beta (Ikbkb), mRNA [NM_010546] KLA 1.88 2.10 2.14 1.83 1.73 1.31 1.19
ATP .81 .74 .55 .49 .59 1.05 .96
KLA/ATP 1.86 1.73 1.39 1.12 .89 1.17 1.24
Ikbkg
KLA  ATP  ATP+KLA
 AK042138 3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630062P04 product:unclassifiable, full insert sequence. [AK042138] KLA .92 .87 .78 .78 .87 .88 .62
ATP .84 .71 .80 .50 1.15 2.33 .61
KLA/ATP .72 .69 .74 .48 1.06 1.97 .68
Ikbkg
KLA  ATP  ATP+KLA
 NM_010547 inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 1, mRNA [NM_010547] KLA 1.51 1.63 1.74 1.83 1.83 1.73 1.72
ATP .80 .79 .82 .75 .66 2.58 2.37
KLA/ATP 1.43 1.42 1.17 1.04 .71 1.54 3.17
Ikbkg
KLA  ATP  ATP+KLA
 NM_178590 inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 2, mRNA [NM_178590] KLA .84 .93 .86 .91 1.03 .89 .88
ATP 1.03 .98 .68 .56 .51 .93 .68
KLA/ATP .89 .81 .55 .52 .41 .67 .65
Il15
KLA  ATP  ATP+KLA
 AB022307 mRNA for shorter isoform of interleukin 15, partial cds. [AB022307] KLA 13.11 12.14 12.05 8.72 4.50 3.62 1.70
ATP 1.04 1.05 1.94 1.72 1.74 3.48 1.69
KLA/ATP 13.23 13.71 21.01 21.43 21.51 10.85 4.55
Il15
KLA  ATP  ATP+KLA
 NM_008357 interleukin 15 (Il15), mRNA [NM_008357] KLA 28.44 24.75 23.34 20.83 11.02 7.27 2.51
ATP 1.00 .96 1.22 1.21 1.24 4.27 1.85
KLA/ATP 24.24 23.93 33.47 31.76 21.73 10.79 11.23
Il15ra
KLA  ATP  ATP+KLA
 NM_008358 interleukin 15 receptor, alpha chain (Il15ra), transcript variant 1, mRNA [NM_008358] KLA 8.74 9.57 10.15 8.79 7.56 7.63 3.77
ATP .96 .93 1.02 1.07 2.02 3.73 1.46
KLA/ATP 9.56 10.41 10.94 10.62 11.08 9.82 8.07
Il1r1
KLA  ATP  ATP+KLA
 NM_008362 interleukin 1 receptor, type I (Il1r1), transcript variant 1, mRNA [NM_008362] KLA 1.20 1.08 1.22 1.52 2.19 2.32 1.61
ATP 1.10 .96 1.18 1.56 8.14 9.56 7.54
KLA/ATP 1.22 1.13 1.37 1.85 4.54 6.85 8.96
Il1r2
KLA  ATP  ATP+KLA
 NM_010555 interleukin 1 receptor, type II (Il1r2), mRNA [NM_010555] KLA 1.05 1.03 1.08 1.13 1.09 1.08 1.14
ATP 1.03 1.08 1.30 1.68 1.38 1.10 1.19
KLA/ATP 1.08 1.14 1.17 1.27 1.10 1.11 2.03
Il2
KLA  ATP  ATP+KLA
 NM_008366 interleukin 2 (Il2), mRNA [NM_008366] KLA .96 .97 .96 1.00 .97 .97 .99
ATP 1.04 1.02 1.00 1.03 .97 .98 .97
KLA/ATP 1.01 .98 .97 1.00 .97 .97 .96
Il2ra
KLA  ATP  ATP+KLA
 AF054581 interleukin 2 receptor mRNA, 3UTR, partial sequence. [AF054581] KLA 1.76 2.05 2.73 2.46 3.58 2.68 1.13
ATP .99 .99 1.00 1.09 1.13 1.14 1.03
KLA/ATP 1.93 2.11 1.32 2.27 1.87 2.13 1.37
Il2ra
KLA  ATP  ATP+KLA
 NM_008367 interleukin 2 receptor, alpha chain (Il2ra), mRNA [NM_008367] KLA 1.33 1.29 1.46 1.43 1.82 1.57 1.15
ATP 1.02 1.03 1.01 1.02 1.01 1.12 1.05
KLA/ATP 1.30 1.46 1.36 1.41 1.22 1.47 1.66
Il2rb
KLA  ATP  ATP+KLA
 NM_008368 interleukin 2 receptor, beta chain (Il2rb), mRNA [NM_008368] KLA .92 1.00 1.00 1.00 .91 .98 1.09
ATP 1.02 .98 1.00 .95 1.02 1.04 1.04
KLA/ATP 1.03 .98 1.01 .99 .94 1.13 1.00
Il2rg
KLA  ATP  ATP+KLA
 NM_013563 interleukin 2 receptor, gamma chain (Il2rg), mRNA [NM_013563] KLA 2.97 2.92 3.73 3.39 4.04 3.45 4.83
ATP 1.25 1.41 1.04 1.82 1.48 1.12 2.89
KLA/ATP 3.65 4.34 2.42 4.70 2.62 2.54 5.15
Il6
KLA  ATP  ATP+KLA
 NM_031168 interleukin 6 (Il6), mRNA [NM_031168] KLA 352.99 378.70 276.81 168.47 59.99 18.66 8.27
ATP 1.04 1.08 2.28 3.69 30.40 161.93 2.11
KLA/ATP 334.28 528.66 ###.## 935.86 302.45 355.36 99.65
Itgal
KLA  ATP  ATP+KLA
 AK156251 activated spleen cDNA, RIKEN full-length enriched library, clone:F830013L17 product:integrin alpha L, full insert sequence [AK156251] KLA 5.36 5.78 4.86 5.55 7.02 8.63 11.12
ATP .99 1.17 1.22 1.57 1.35 1.95 3.79
KLA/ATP 5.42 5.89 4.95 5.91 3.96 4.93 10.15
Itgal
KLA  ATP  ATP+KLA
 NM_008400 integrin alpha L (Itgal), mRNA [NM_008400] KLA 4.48 5.17 5.28 5.82 7.82 8.09 16.96
ATP 1.03 1.06 1.24 1.44 1.34 2.02 4.59
KLA/ATP 4.71 5.63 5.49 5.60 3.66 4.65 17.76
Itgb2
KLA  ATP  ATP+KLA
 NM_008404 integrin beta 2 (Itgb2), mRNA [NM_008404] KLA .78 .78 .97 .74 1.04 .94 1.14
ATP 1.24 1.23 .79 .95 1.12 .84 1.10
KLA/ATP .99 1.01 .60 .83 .78 .73 .99
Itgb2l
KLA  ATP  ATP+KLA
 NM_008405 integrin beta 2-like (Itgb2l), mRNA [NM_008405] KLA .87 .98 .98 1.00 1.05 1.07 1.10
ATP 1.24 1.23 1.13 1.14 1.29 1.05 1.05
KLA/ATP 1.02 1.08 1.08 1.06 .98 .93 .95
Jak1
KLA  ATP  ATP+KLA
 AK029232 0 day neonate head cDNA, RIKEN full-length enriched library, clone:4831433J01 product:Janus kinase 1, full insert sequence. [AK029232] KLA 1.25 1.13 1.19 1.31 1.24 1.17 1.14
ATP 1.01 1.11 .96 1.38 1.06 1.26 1.05
KLA/ATP 1.19 1.29 1.27 1.59 1.18 1.38 1.24
Jak1
KLA  ATP  ATP+KLA
 NM_146145 Janus kinase 1 (Jak1), mRNA [NM_146145] KLA 1.71 1.75 1.79 1.81 1.72 1.37 1.21
ATP 1.03 1.01 .75 1.04 1.32 1.90 1.14
KLA/ATP 1.84 1.73 1.49 2.07 2.01 1.83 1.68
Jak3
KLA  ATP  ATP+KLA
 NM_010589 Janus kinase 3 (Jak3), mRNA [NM_010589] KLA 1.46 1.56 1.79 1.62 2.05 1.72 1.65
ATP 1.11 1.19 .84 1.25 .82 .61 .71
KLA/ATP 1.76 1.82 1.10 1.74 .93 .83 1.01
Jun
KLA  ATP  ATP+KLA
 NM_010591 Jun oncogene (Jun), mRNA [NM_010591] KLA 1.08 .96 1.09 1.09 .75 .88 .81
ATP 1.26 1.48 4.45 8.73 4.02 1.16 1.99
KLA/ATP 1.12 1.38 3.52 5.17 3.32 .49 1.42
Kras
KLA  ATP  ATP+KLA
 NM_021284 v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), mRNA [NM_021284] KLA .53 .49 .40 .42 .49 .95 1.05
ATP .98 1.01 1.16 1.17 1.39 1.29 1.74
KLA/ATP .50 .47 .50 .56 1.00 1.24 1.58
Lck
KLA  ATP  ATP+KLA
 NM_010693 lymphocyte protein tyrosine kinase (Lck), mRNA [NM_010693] KLA 18.74 17.97 23.64 20.20 17.34 8.29 1.29
ATP 1.00 1.04 1.28 1.30 1.48 2.55 1.44
KLA/ATP 21.76 24.22 23.73 23.04 22.66 12.06 2.90
LOC67670
8
KLA  ATP  ATP+KLA
 XM_992322 ref|PREDICTED: Mus musculus similar to class I (Qa) Q2k antigen (LOC676708), mRNA [XM_992322] KLA 2.18 2.22 2.32 2.27 2.28 2.77 3.62
ATP 1.04 1.17 1.17 2.19 1.83 1.75 2.30
KLA/ATP 2.20 2.44 2.25 3.41 2.30 2.63 5.00
Lta
KLA  ATP  ATP+KLA
 NM_010735 lymphotoxin A (Lta), mRNA [NM_010735] KLA 1.95 2.18 2.41 2.18 2.50 2.26 1.79
ATP 1.01 1.00 1.10 1.55 1.24 1.09 1.07
KLA/ATP 2.16 2.23 1.85 2.11 1.60 1.31 1.33
Ltbr
KLA  ATP  ATP+KLA
 NM_010736 lymphotoxin B receptor (Ltbr), mRNA [NM_010736] KLA .78 .77 .80 .95 1.08 1.39 1.36
ATP .94 .86 1.00 .83 .74 1.18 1.37
KLA/ATP .69 .71 .74 .68 .85 1.04 1.69
Mad2l1
KLA  ATP  ATP+KLA
 NM_019499 MAD2 (mitotic arrest deficient, homolog)-like 1 (yeast) (Mad2l1), mRNA [NM_019499] KLA .70 .68 .73 .71 .52 .41 .28
ATP 1.06 1.02 1.43 1.25 1.03 .53 .19
KLA/ATP .70 .69 .99 .84 .70 .43 .18
Mad2l1
KLA  ATP  ATP+KLA
 U83902 mitotic checkpoint component Mad2 mRNA, complete cds. [U83902] KLA .67 .68 .67 .60 .50 .39 .27
ATP .95 .97 1.28 1.28 .88 .54 .19
KLA/ATP .62 .66 .84 .91 .62 .41 .18
Map2k4
KLA  ATP  ATP+KLA
 NM_009157 mitogen-activated protein kinase kinase 4 (Map2k4), mRNA [NM_009157] KLA 3.67 3.75 4.23 3.90 3.30 1.87 1.12
ATP 1.05 1.11 1.04 .93 1.16 2.62 1.02
KLA/ATP 3.70 4.13 3.27 4.13 2.98 3.03 1.82
Map3k1
KLA  ATP  ATP+KLA
 NM_011945 mitogen-activated protein kinase kinase kinase 1 (Map3k1), mRNA [NM_011945] KLA .30 .25 .37 .56 .68 1.07 .85
ATP .88 .86 1.26 1.04 1.07 .77 .78
KLA/ATP .28 .24 .59 .99 1.49 .97 1.24
Map3k14
KLA  ATP  ATP+KLA
 NM_016896 mitogen-activated protein kinase kinase kinase 14 (Map3k14), mRNA [NM_016896] KLA .32 .30 .40 .52 1.08 1.14 .94
ATP 1.18 1.24 1.13 .85 .82 .84 .99
KLA/ATP .33 .30 .34 .50 1.02 .84 1.43
Map3k3
KLA  ATP  ATP+KLA
 NM_011947 mitogen-activated protein kinase kinase kinase 3 (Map3k3), mRNA [NM_011947] KLA .60 .63 .60 .58 .81 1.03 1.26
ATP .97 .91 .55 .58 .71 .81 .99
KLA/ATP .68 .57 .42 .53 .61 .85 1.23
Mapk10
KLA  ATP  ATP+KLA
 AK076990 adult male testis cDNA, RIKEN full-length enriched library, clone:4930597C01 product:mitogen activated protein kinase 10, full insert sequence. [AK076990] KLA 1.03 1.05 .98 1.04 .94 .95 1.02
ATP 1.00 .99 1.06 .97 1.01 .96 .99
KLA/ATP 1.07 1.01 .95 1.05 .82 .95 .87
Mapk10
KLA  ATP  ATP+KLA
 NM_009158 mitogen-activated protein kinase 10 (Mapk10), transcript variant 1, mRNA [NM_009158] KLA .95 1.00 .97 1.01 .99 1.01 .95
ATP 1.01 1.02 .98 1.01 1.04 1.01 .99
KLA/ATP 1.05 .99 1.01 .98 .92 .97 .98
Mapk8
KLA  ATP  ATP+KLA
 AK162915 adult male spinal cord cDNA, RIKEN full-length enriched library, clone:A330031O19 product:mitogen activated protein kinase 8, full insert sequence [AK162915] KLA .94 .86 .80 .83 .77 .85 .83
ATP 1.08 1.12 .94 .80 .83 .71 .75
KLA/ATP .83 .81 .80 .74 .74 .75 .67
Mapk8
KLA  ATP  ATP+KLA
 AK163829 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130070A06 product:mitogen activated protein kinase 8, full insert sequence [AK163829] KLA .65 .61 .66 .70 .90 1.02 1.03
ATP .99 .94 1.68 1.44 1.75 1.84 1.10
KLA/ATP .63 .67 1.11 1.00 2.01 1.68 1.15
Mapk8
KLA  ATP  ATP+KLA
 NM_016700 mitogen-activated protein kinase 8 (Mapk8), mRNA [NM_016700] KLA .96 1.00 .94 .96 .94 .99 1.04
ATP 1.01 1.05 1.01 .99 1.03 .98 1.02
KLA/ATP .96 .97 .96 .97 .93 .94 .96
Mapk9
KLA  ATP  ATP+KLA
 NM_016961 mitogen-activated protein kinase 9 (Mapk9), transcript variant 2, mRNA [NM_016961] KLA 1.28 1.37 1.59 1.60 1.61 1.43 1.38
ATP 1.03 .99 .74 .71 .79 1.20 1.01
KLA/ATP 1.53 1.30 1.07 .99 .83 1.10 1.40
Mapk9
KLA  ATP  ATP+KLA
 NM_207692 mitogen-activated protein kinase 9 (Mapk9), transcript variant 1, mRNA [NM_207692] KLA 1.39 1.53 1.69 1.69 1.55 1.44 1.51
ATP .95 .92 .75 .85 .70 1.46 1.17
KLA/ATP 1.37 1.35 .99 1.18 .91 1.22 1.62
Mm.15898
1
KLA  ATP  ATP+KLA
 142388182 Unknown KLA .25 .22 .31 .50 .85 1.11 .83
ATP 1.02 .94 1.31 .76 .73 .96 .92
KLA/ATP .24 .22 .34 .38 1.16 .96 1.23
Mm.1741
KLA  ATP  ATP+KLA
 31982052 Unknown KLA 4.05 3.90 3.12 3.55 4.00 3.37 2.25
ATP 1.01 1.01 1.44 2.36 3.07 3.54 1.27
KLA/ATP 4.19 3.74 4.02 4.02 3.13 2.82 3.33
Mm.19506
1
KLA  ATP  ATP+KLA
 76253707 Unknown KLA 5.35 4.83 5.36 6.20 6.87 9.80 7.83
ATP .97 .90 .96 .77 .80 3.98 5.87
KLA/ATP 4.63 4.51 4.51 3.75 4.39 7.21 16.38
Mm.21036
1
KLA  ATP  ATP+KLA
 158508719 Unknown KLA 1.12 1.15 1.09 1.20 1.18 1.33 1.23
ATP 1.05 1.18 1.10 1.41 1.26 1.25 1.23
KLA/ATP 1.22 1.40 1.22 1.54 1.24 1.28 1.49
Mm.21312
8
KLA  ATP  ATP+KLA
 141801344 Unknown KLA .96 .95 .83 .77 .52 .99 1.32
ATP .80 .82 1.09 .80 .83 1.19 1.46
KLA/ATP .78 .92 .98 .62 .71 .94 1.41
Mm.21516
1
KLA  ATP  ATP+KLA
 141801906 Unknown KLA 1.08 1.09 1.10 1.08 1.09 1.05 1.12
ATP .95 .94 1.05 1.16 1.05 1.08 1.14
KLA/ATP 1.07 1.15 1.16 1.16 1.10 1.14 1.14
Mm.23522
KLA  ATP  ATP+KLA
 124487357 Unknown KLA 1.02 1.00 .97 .98 1.00 .96 .93
ATP .98 .99 1.06 .97 .94 1.00 1.03
KLA/ATP .94 1.01 1.03 1.01 1.04 1.02 1.01
Mm.24004
7
KLA  ATP  ATP+KLA
 118130430 Unknown KLA 1.09 1.07 1.01 1.00 1.04 1.05 .97
ATP .98 1.00 1.05 .97 1.05 1.02 1.05
KLA/ATP .98 1.04 1.16 1.06 1.06 .96 1.02
Mm.24600
3
KLA  ATP  ATP+KLA
 161086914 Unknown KLA 10.04 10.23 11.14 8.37 5.02 2.48 2.15
ATP .96 1.08 1.11 1.79 4.88 8.01 1.29
KLA/ATP 9.96 11.13 9.87 10.92 7.51 7.35 6.26
Mm.25381
9
KLA  ATP  ATP+KLA
 118130676 Unknown KLA 1.81 1.88 1.96 1.62 1.89 2.44 1.56
ATP .92 .91 1.24 1.01 1.16 2.06 1.95
KLA/ATP 1.62 1.86 1.86 1.41 1.89 2.37 1.97
Mm.26232
7
KLA  ATP  ATP+KLA
 118130063 Unknown KLA .91 .88 .82 .99 .84 .98 .82
ATP .84 .72 .77 .54 .54 .50 .72
KLA/ATP .74 .71 .74 .50 .71 .60 .39
Mm.27304
9
KLA  ATP  ATP+KLA
 119672895 Unknown KLA .23 .22 .22 .22 .30 .51 .16
ATP 1.08 1.05 .88 .78 .47 .09 .20
KLA/ATP .28 .22 .21 .24 .26 .22 .12
Mm.30793
2
KLA  ATP  ATP+KLA
 160333363 Unknown KLA .13 .12 .14 .16 .15 .18 .15
ATP .92 .94 1.12 .93 .58 .29 .31
KLA/ATP .11 .11 .18 .20 .28 .20 .19
Mm.33138
9
KLA  ATP  ATP+KLA
 158508469 Unknown KLA .80 .79 .81 .82 .72 .64 .50
ATP .95 .85 .56 .48 .30 .33 .46
KLA/ATP .71 .64 .50 .41 .33 .32 .42
Mm.41137
KLA  ATP  ATP+KLA
 148747308 Unknown KLA 1.03 1.00 .95 .92 1.04 .98 .96
ATP 1.02 .98 .98 .90 .95 .92 1.07
KLA/ATP .91 .89 1.01 .95 1.00 .96 .99
Mm.41292
2
KLA  ATP  ATP+KLA
 145966829 Unknown KLA 3.65 3.76 3.75 3.79 3.42 1.75 1.10
ATP 1.11 1.17 1.04 .90 1.37 2.90 1.00
KLA/ATP 3.31 3.97 3.38 3.84 3.04 3.31 2.09
Mm.43967
5
KLA  ATP  ATP+KLA
 133778954 Unknown KLA 1.76 1.74 1.70 1.72 1.75 2.14 3.19
ATP 1.00 1.01 1.18 1.28 1.25 1.48 1.84
KLA/ATP 1.67 1.64 1.70 1.79 1.63 2.04 3.36
Mm.43967
5
KLA  ATP  ATP+KLA
 149275074 Unknown KLA 2.17 2.23 2.26 2.58 2.26 2.10 1.43
ATP .96 .91 1.12 .90 .70 1.10 1.47
KLA/ATP 1.96 2.10 1.92 1.51 1.12 1.35 1.99
Mm.44165
1
KLA  ATP  ATP+KLA
 160333403 Unknown KLA 5.45 5.27 5.02 6.34 6.63 10.05 8.10
ATP .91 .84 .96 .75 .78 3.91 6.03
KLA/ATP 4.29 4.38 4.50 3.55 4.22 7.22 17.63
Mm.45044
KLA  ATP  ATP+KLA
 133892959 Unknown KLA .51 .47 .52 .83 1.25 1.16 .60
ATP 1.09 .78 .80 .63 .83 .89 .41
KLA/ATP .49 .42 .44 .39 .89 1.04 .41
Mm.45825
9
KLA  ATP  ATP+KLA
 116292181 Unknown KLA .84 .86 .91 .85 .98 .98 1.00
ATP 1.05 1.06 .94 .95 1.00 .89 .89
KLA/ATP .92 .84 .87 .93 .91 .92 .82
Mm.46781
1
KLA  ATP  ATP+KLA
 153792000 Unknown KLA 1.43 1.25 1.10 1.33 1.29 1.01 .59
ATP 1.08 1.15 1.09 1.08 1.12 .86 .50
KLA/ATP 1.12 1.24 1.55 1.47 1.50 1.15 .40
Mm.47124
2
KLA  ATP  ATP+KLA
 31542487 Unknown KLA .72 .67 .68 .65 .63 .80 1.06
ATP .89 .87 .96 .83 .82 .68 .95
KLA/ATP .62 .60 .60 .52 .67 .64 .58
Mm.47351
0
KLA  ATP  ATP+KLA
 162287332 Unknown KLA 4.46 4.82 5.29 4.00 2.26 1.25 1.10
ATP 1.24 1.72 1.02 2.08 1.66 2.53 .55
KLA/ATP 6.11 7.67 4.29 6.99 3.11 2.86 2.30
Mm.4769
KLA  ATP  ATP+KLA
 31542830 Unknown KLA .93 .99 .86 .85 .75 .83 .80
ATP 1.01 1.00 .91 .83 .96 1.15 .84
KLA/ATP .95 .95 .92 .81 .85 1.12 .87
Mm.56964
KLA  ATP  ATP+KLA
 144227223 Unknown KLA .96 .99 1.00 .99 .97 1.01 1.05
ATP .99 .94 1.00 .94 .97 .99 .91
KLA/ATP 1.05 .97 1.02 .97 .91 1.00 1.02
Mras
KLA  ATP  ATP+KLA
 NM_008624 muscle and microspikes RAS (Mras), mRNA [NM_008624] KLA .77 .76 .75 .84 .92 .87 1.35
ATP 1.02 1.00 1.11 1.14 .87 .79 .80
KLA/ATP .77 .77 .86 .78 .69 .63 .61
Msx1
KLA  ATP  ATP+KLA
 NM_010835 homeobox, msh-like 1 (Msx1), mRNA [NM_010835] KLA 1.11 1.06 .85 1.00 .93 .96 1.04
ATP 1.09 1.07 1.02 1.26 1.03 .96 1.03
KLA/ATP 1.02 1.04 .93 1.11 1.06 1.03 1.17
Msx1
KLA  ATP  ATP+KLA
 X59251 gb|Mouse Hox-7 mRNA for homeobox protein, homolog of Drosophila Msh gene. [X59251] KLA 1.01 1.00 .98 .99 1.00 1.01 .99
ATP .99 1.01 1.03 .98 1.02 1.02 .99
KLA/ATP 1.00 1.03 1.03 1.01 1.04 .98 1.01
Msx2
KLA  ATP  ATP+KLA
 NM_013601 homeobox, msh-like 2 (Msx2), mRNA [NM_013601] KLA 1.00 1.00 1.00 .97 1.00 1.00 .99
ATP 1.01 .97 .99 .97 1.00 .99 1.01
KLA/ATP 1.02 .99 1.00 .98 .99 .99 1.01
Msx3
KLA  ATP  ATP+KLA
 NM_010836 homeobox, msh-like 3 (Msx3), mRNA [NM_010836] KLA 1.00 .98 .95 .99 1.02 .99 .98
ATP .98 .99 .97 .93 .96 1.03 1.01
KLA/ATP 1.01 .98 1.03 .97 .95 .96 1.04
Myb
KLA  ATP  ATP+KLA
 AK036518 adult male bone cDNA, RIKEN full-length enriched library, clone:9830125P17 product:myeloblastosis oncogene, full insert sequence. [AK036518] KLA 1.02 .96 1.03 1.00 .96 1.07 .99
ATP 1.07 .96 1.03 .99 .96 1.03 1.00
KLA/ATP 1.04 1.07 .83 .93 1.06 1.03 1.00
Myb
KLA  ATP  ATP+KLA
 M16449 gb|Mouse myb mRNA, complete cds [M16449] KLA .97 1.07 1.09 1.01 1.01 1.02 .98
ATP 1.06 .98 1.05 1.06 .91 .91 .84
KLA/ATP 1.08 1.07 .80 1.03 1.01 .92 .90
Myb
KLA  ATP  ATP+KLA
 NM_010848 myeloblastosis oncogene (Myb), mRNA [NM_010848] KLA 1.07 1.05 1.11 1.09 1.06 .99 .91
ATP .99 1.05 1.05 .95 .94 .93 .82
KLA/ATP 1.04 1.09 1.07 .97 .94 .95 .82
Mybl1
KLA  ATP  ATP+KLA
 NM_008651 myeloblastosis oncogene-like 1 (Mybl1), mRNA [NM_008651] KLA 1.04 1.01 .98 1.02 .97 .96 .90
ATP 1.04 1.01 .97 1.07 1.02 1.03 .94
KLA/ATP 1.06 .97 .96 1.06 1.03 1.01 .96
Mybl1
KLA  ATP  ATP+KLA
 X82327 gb|M.musculus mRNA for A-Myb protein. [X82327] KLA .99 .93 .99 .98 .97 .93 1.03
ATP 1.02 1.01 .94 .90 1.00 .98 .93
KLA/ATP .98 1.06 .92 .93 .97 1.02 .92
Mybl2
KLA  ATP  ATP+KLA
 NM_008652 myeloblastosis oncogene-like 2 (Mybl2), mRNA [NM_008652] KLA .39 .38 .39 .36 .30 .32 .27
ATP 1.13 1.13 .83 1.11 .61 .33 .25
KLA/ATP .45 .39 .41 .40 .38 .34 .39
Myc
KLA  ATP  ATP+KLA
 NM_010849 myelocytomatosis oncogene (Myc), mRNA [NM_010849] KLA .38 .31 .45 .45 .49 .35 .33
ATP 1.05 1.09 1.72 4.41 1.28 .45 .76
KLA/ATP .37 .30 .44 1.23 .34 .17 .19
Nfat5
KLA  ATP  ATP+KLA
 AK172011 activated spleen cDNA, RIKEN full-length enriched library, clone:F830029B05 product:nuclear factor of activated T-cells 5, full insert sequence. [AK172011] KLA .94 .90 .93 .93 1.28 1.27 1.16
ATP .95 .76 1.13 1.27 1.93 2.21 1.18
KLA/ATP .85 .84 1.10 .92 1.53 1.63 1.66
Nfat5
KLA  ATP  ATP+KLA
 NM_018823 nuclear factor of activated T-cells 5 (Nfat5), transcript variant b, mRNA [NM_018823] KLA .95 1.01 .99 1.03 1.08 1.13 1.19
ATP 1.05 1.22 1.67 1.98 1.74 1.38 1.17
KLA/ATP 1.03 1.07 1.34 1.38 1.30 1.19 1.40
Nfat5
KLA  ATP  ATP+KLA
 NM_133957 nuclear factor of activated T-cells 5 (Nfat5), transcript variant a, mRNA [NM_133957] KLA 1.07 1.07 1.00 .96 1.42 1.36 1.51
ATP 1.15 1.19 1.81 4.36 6.34 3.49 1.12
KLA/ATP 1.27 1.08 1.87 2.72 3.58 3.05 2.07
Nfatc1
KLA  ATP  ATP+KLA
 NM_016791 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (Nfatc1), transcript variant 1, mRNA [NM_016791] KLA .71 .66 .68 .62 .63 .67 .81
ATP 1.12 1.29 1.15 1.21 .83 .63 1.25
KLA/ATP .78 .79 .65 .74 .59 .45 .92
Nfatc1
KLA  ATP  ATP+KLA
 NM_198429 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (Nfatc1), transcript variant 2, mRNA [NM_198429] KLA .49 .41 .50 .43 .50 .78 .69
ATP 1.05 .81 .84 .54 .60 .38 .69
KLA/ATP .46 .37 .45 .32 .62 .39 .61
Nfatc2
KLA  ATP  ATP+KLA
 AK081853 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130082H17 product:nuclear factor of activated T-cells, cytoplasmic 2, full insert sequence. [AK081853] KLA .56 .52 .59 .61 .78 .78 .66
ATP 1.19 1.27 .67 .65 .62 .53 .79
KLA/ATP .52 .49 .71 .57 .65 .52 .53
Nfatc2
KLA  ATP  ATP+KLA
 NM_001037177 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 (Nfatc2), transcript variant 2, mRNA [NM_001037177] KLA .84 .79 .74 .82 .89 .98 .80
ATP 1.06 1.13 1.01 .87 .86 .83 1.10
KLA/ATP .76 .72 .89 .84 .84 .81 .84
Nfatc2
KLA  ATP  ATP+KLA
 NM_010899 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 (Nfatc2), transcript variant 1, mRNA [NM_010899] KLA .90 .91 .86 .91 .86 1.07 1.00
ATP 1.08 1.11 1.45 1.04 .88 .85 1.18
KLA/ATP .85 .89 .92 .89 .93 .84 1.13
Nfatc3
KLA  ATP  ATP+KLA
 AK084848 13 days embryo lung cDNA, RIKEN full-length enriched library, clone:D430001G08 product:nuclear factor of activated T-cells, cytoplasmic 3, full insert sequence. [AK084848] KLA 1.08 .96 .98 1.00 .98 1.03 .98
ATP 1.00 1.03 .93 .92 .92 1.11 .98
KLA/ATP 1.01 .87 1.10 .97 .96 .96 .99
Nfatc3
KLA  ATP  ATP+KLA
 NM_010901 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 (Nfatc3), mRNA [NM_010901] KLA .77 .68 .67 .77 .85 .90 1.04
ATP 1.01 .95 .89 .70 .70 .92 .98
KLA/ATP .77 .66 .64 .59 .82 .90 .90
Nfatc4
KLA  ATP  ATP+KLA
 AK014164 13 days embryo head cDNA, RIKEN full-length enriched library, clone:3110041H08 product:nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4, full insert sequence. [AK014164] KLA .90 .92 .91 1.00 .99 .98 .95
ATP .90 1.03 .96 .98 .95 .97 1.00
KLA/ATP .95 .87 1.00 .98 .96 .96 .92
Nfatc4
KLA  ATP  ATP+KLA
 NM_023699 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4 (Nfatc4), mRNA [NM_023699] KLA 1.28 1.38 1.44 1.58 1.40 1.41 1.46
ATP 1.03 1.06 1.23 1.24 1.32 1.40 1.41
KLA/ATP 1.30 1.38 1.47 1.28 1.38 1.40 1.63
Nfkb1
KLA  ATP  ATP+KLA
 BC050841 nuclear factor of kappa light chain gene enhancer in B-cells 1, p105, mRNA (cDNA clone IMAGE:6392793), complete cds. [BC050841] KLA 5.81 4.96 4.77 3.21 3.37 2.00 1.71
ATP 1.39 1.52 3.25 12.63 13.64 4.80 1.08
KLA/ATP 7.21 8.69 19.53 23.93 11.70 2.85 2.01
Nfkb1
KLA  ATP  ATP+KLA
 M57999 gb|Mouse transcription factor NF-kappa-B DNA binding subunit mRNA, complete cds. [M57999] KLA 8.55 7.87 7.35 6.13 3.51 1.85 1.38
ATP .98 .96 1.21 3.06 5.29 4.67 .69
KLA/ATP 7.32 7.20 8.71 10.82 5.55 2.77 1.54
Nfkb2
KLA  ATP  ATP+KLA
 NM_019408 nuclear factor of kappa light polypeptide gene enhancer in B-cells 2, p49/p100 (Nfkb2), mRNA [NM_019408] KLA 7.31 7.92 7.95 6.42 6.41 4.42 2.81
ATP .99 .98 .72 1.48 2.80 5.31 1.44
KLA/ATP 8.25 7.93 6.51 7.68 5.08 4.38 4.86
Nfkbia
KLA  ATP  ATP+KLA
 NM_010907 nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (Nfkbia), mRNA [NM_010907] KLA 18.65 18.46 13.63 17.88 14.25 9.17 7.92
ATP .91 1.09 7.11 32.39 17.44 10.49 1.72
KLA/ATP 15.57 17.66 15.73 23.91 13.83 10.73 9.48
Nfyb
KLA  ATP  ATP+KLA
 NM_010914 nuclear transcription factor-Y beta (Nfyb), mRNA [NM_010914] KLA 1.38 1.22 1.12 1.30 1.07 .91 .68
ATP 1.09 1.01 .98 .89 .96 1.16 .64
KLA/ATP 1.17 1.21 1.52 1.18 .95 .82 .77
Nras
KLA  ATP  ATP+KLA
 NM_010937 neuroblastoma ras oncogene (Nras), mRNA [NM_010937] KLA 1.20 1.22 1.27 1.20 1.09 .91 .84
ATP .98 .91 .69 .61 .59 .67 .78
KLA/ATP 1.22 1.14 .97 .79 .73 .61 .72
Nrp1
KLA  ATP  ATP+KLA
 AK040447 0 day neonate thymus cDNA, RIKEN full-length enriched library, clone:A430096P05 product:neuropilin, full insert sequence. [AK040447] KLA .33 .32 .34 .36 .34 .50 .45
ATP .92 .85 1.03 .87 .56 .82 .82
KLA/ATP .31 .33 .44 .37 .41 .56 .58
Nrp1
KLA  ATP  ATP+KLA
 NM_008737 neuropilin 1 (Nrp1), mRNA [NM_008737] KLA .53 .52 .45 .39 .25 .25 .25
ATP 1.14 1.11 .84 .98 .64 .66 .66
KLA/ATP .64 .54 .39 .48 .36 .40 .36
Pcaf
KLA  ATP  ATP+KLA
 NM_020005 p300/CBP-associated factor (Pcaf), mRNA [NM_020005] KLA 2.47 2.38 3.01 3.89 3.93 2.64 1.24
ATP 1.14 1.21 1.23 .99 .93 1.29 .91
KLA/ATP 2.58 2.82 3.67 2.48 2.42 2.28 2.26
Pcna
KLA  ATP  ATP+KLA
 NM_011045 proliferating cell nuclear antigen (Pcna), mRNA [NM_011045] KLA .70 .69 .73 .56 .46 .66 .55
ATP .98 .95 1.12 .81 .74 .49 .92
KLA/ATP .69 .66 .78 .60 .63 .59 .62
Pdgfa
KLA  ATP  ATP+KLA
 NM_008808 platelet derived growth factor, alpha (Pdgfa), mRNA [NM_008808] KLA .63 .56 .42 .34 .31 .33 .52
ATP .89 .80 .69 1.23 5.97 3.99 2.73
KLA/ATP .64 .53 .43 .77 3.48 3.78 2.37
Pdgfb
KLA  ATP  ATP+KLA
 NM_011057 platelet derived growth factor, B polypeptide (Pdgfb), mRNA [NM_011057] KLA .45 .43 .38 .46 .69 .48 .58
ATP .94 .95 .66 .74 .67 .77 1.06
KLA/ATP .43 .43 .37 .39 .52 .55 1.64
Pdgfra
KLA  ATP  ATP+KLA
 NM_011058 platelet derived growth factor receptor, alpha polypeptide (Pdgfra), transcript variant 1, mRNA [NM_011058] KLA 1.02 1.05 1.02 1.01 1.03 1.03 1.01
ATP 1.01 1.02 1.03 1.04 1.00 1.01 1.01
KLA/ATP 1.01 1.01 .99 1.03 1.02 1.03 1.01
Pdgfrb
KLA  ATP  ATP+KLA
 NM_008809 platelet derived growth factor receptor, beta polypeptide (Pdgfrb), mRNA [NM_008809] KLA 4.85 5.49 4.56 3.94 3.71 2.05 1.51
ATP .99 1.00 1.11 1.27 1.02 1.83 1.23
KLA/ATP 5.09 5.86 4.30 2.51 1.74 1.84 3.23
Pik3ca
KLA  ATP  ATP+KLA
 ENSMUST00000108243 ens|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (EC 2.7.1.153) (PI3-kinase p110 subunit alpha) (PtdIns-3- kinase p110) (PI3K). [Source:Uniprot/SWISSPROT;Acc:P42337] [ENSMUST00000108243] KLA 1.07 1.01 .91 .90 .98 .96 .86
ATP 1.03 .87 1.12 .63 1.22 1.86 .60
KLA/ATP 1.05 .82 .91 .61 1.17 1.26 .63
Pik3ca
KLA  ATP  ATP+KLA
 NM_008839 phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca), mRNA [NM_008839] KLA 1.15 1.11 1.05 .82 .99 1.03 1.27
ATP .98 1.00 .79 .75 .96 1.32 1.10
KLA/ATP 1.10 .98 .64 .72 .80 1.20 1.41
Pik3cb
KLA  ATP  ATP+KLA
 NM_029094 phosphatidylinositol 3-kinase, catalytic, beta polypeptide (Pik3cb), mRNA [NM_029094] KLA 1.06 1.06 1.03 .73 .68 .98 1.69
ATP 1.04 1.21 .95 1.02 .85 .93 1.73
KLA/ATP 1.15 1.27 .73 .83 .58 .81 1.81
Pik3cd
KLA  ATP  ATP+KLA
 NM_008840 phosphatidylinositol 3-kinase catalytic delta polypeptide (Pik3cd), transcript variant 1, mRNA [NM_008840] KLA 2.28 2.42 3.10 4.17 3.35 2.31 1.34
ATP 1.02 .91 .99 .63 .30 .67 .80
KLA/ATP 2.14 2.23 2.70 1.51 1.17 .85 .72
Pik3cd
KLA  ATP  ATP+KLA
 U86587 phosphatidylinositol 3-kinase catalytic subunit p110 delta mRNA, complete cds. [U86587] KLA 2.21 2.24 3.71 3.17 3.67 2.66 1.48
ATP 1.00 1.03 .93 .96 .46 .75 .97
KLA/ATP 2.27 2.32 1.97 2.02 1.01 .99 .98
Pik3cg
KLA  ATP  ATP+KLA
 NM_020272 phosphoinositide-3-kinase, catalytic, gamma polypeptide (Pik3cg), mRNA [NM_020272] KLA .53 .53 .61 .64 .97 .86 .79
ATP 1.01 1.13 .88 .89 .52 .53 .53
KLA/ATP .58 .53 .43 .60 .40 .43 .62
Pik3r1
KLA  ATP  ATP+KLA
 NM_001077495 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript variant 2, mRNA [NM_001077495] KLA 1.05 1.07 1.03 1.00 1.01 1.20 .85
ATP .97 1.02 1.48 1.42 1.76 1.33 1.23
KLA/ATP 1.11 1.12 1.06 1.17 1.24 .99 1.12
Pik3r2
KLA  ATP  ATP+KLA
 NM_008841 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) (Pik3r2), mRNA [NM_008841] KLA .50 .50 .48 .43 .46 .66 .75
ATP .78 .68 .45 .43 .28 .57 1.37
KLA/ATP .49 .38 .32 .33 .38 .67 1.10
Pik3r3
KLA  ATP  ATP+KLA
 NM_181585 phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) (Pik3r3), mRNA [NM_181585] KLA 1.59 1.49 1.37 1.17 1.05 1.55 1.41
ATP 1.12 1.00 1.33 1.70 2.01 2.37 2.02
KLA/ATP 1.63 1.54 1.58 1.70 2.43 2.68 1.92
Pik3r5
KLA  ATP  ATP+KLA
 NM_177320 phosphoinositide-3-kinase, regulatory subunit 5, p101 (Pik3r5), mRNA [NM_177320] KLA 3.57 3.58 4.16 3.54 4.11 2.59 2.39
ATP 1.08 1.08 .93 1.67 3.11 1.88 1.34
KLA/ATP 3.91 3.70 3.30 3.80 2.70 2.04 3.00
Polb
KLA  ATP  ATP+KLA
 BC006681 polymerase (DNA directed), beta, mRNA (cDNA clone IMAGE:3581916), complete cds [BC006681] KLA 1.62 1.31 1.52 1.37 1.57 1.35 1.17
ATP 1.04 1.03 .82 .63 .73 1.00 1.07
KLA/ATP 1.63 1.37 1.02 .72 .89 1.20 1.19
Polb
KLA  ATP  ATP+KLA
 NM_011130 polymerase (DNA directed), beta (Polb), mRNA [NM_011130] KLA 1.81 1.86 2.02 2.10 2.36 2.05 1.64
ATP .99 .99 1.19 1.34 1.16 1.04 1.62
KLA/ATP 1.80 1.83 2.05 2.17 2.03 1.73 2.49
Pold1
KLA  ATP  ATP+KLA
 NM_011131 polymerase (DNA directed), delta 1, catalytic subunit (Pold1), mRNA [NM_011131] KLA .24 .21 .20 .18 .18 .29 .36
ATP 1.05 1.05 .96 .99 .52 .26 .32
KLA/ATP .26 .22 .21 .22 .16 .17 .18
Pold2
KLA  ATP  ATP+KLA
 NM_008894 polymerase (DNA directed), delta 2, regulatory subunit (Pold2), mRNA [NM_008894] KLA .77 .83 .69 .68 .59 .49 .57
ATP 1.05 1.09 .97 1.24 .89 .44 .43
KLA/ATP .79 .78 .70 .84 .60 .41 .30
Pold3
KLA  ATP  ATP+KLA
 NM_133692 polymerase (DNA-directed), delta 3, accessory subunit (Pold3), mRNA [NM_133692] KLA 1.14 1.07 1.22 1.22 1.12 1.40 1.10
ATP .99 .95 1.17 .89 1.46 1.74 1.55
KLA/ATP 1.01 1.08 1.54 1.28 1.86 2.34 2.11
Pold4
KLA  ATP  ATP+KLA
 NM_027196 polymerase (DNA-directed), delta 4 (Pold4), mRNA [NM_027196] KLA .81 .88 .80 .78 .85 1.04 1.40
ATP .97 1.07 1.12 1.37 1.19 .86 1.27
KLA/ATP .85 .90 .89 1.07 .90 .94 1.62
Pole
KLA  ATP  ATP+KLA
 AK086490 15 days embryo head cDNA, RIKEN full-length enriched library, clone:D930032B21 product:DNA polymerase epsilon, full insert sequence. [AK086490] KLA 1.00 1.00 1.04 .96 .94 .99 1.04
ATP .97 .95 .91 .95 .97 1.06 .95
KLA/ATP .96 .93 1.00 1.01 1.08 1.02 1.01
Pole
KLA  ATP  ATP+KLA
 NM_011132 polymerase (DNA directed), epsilon (Pole), mRNA [NM_011132] KLA .50 .44 .38 .31 .25 .21 .17
ATP 1.12 1.03 1.28 .89 .68 .30 .16
KLA/ATP .45 .44 .56 .38 .30 .21 .14
Pole2
KLA  ATP  ATP+KLA
 NM_011133 polymerase (DNA directed), epsilon 2 (p59 subunit) (Pole2), mRNA [NM_011133] KLA .25 .24 .22 .21 .21 .37 .34
ATP .93 .98 1.11 1.00 .36 .30 .35
KLA/ATP .22 .22 .29 .30 .26 .28 .19
Pole3
KLA  ATP  ATP+KLA
 BC034004 polymerase (DNA directed), epsilon 3 (p17 subunit), mRNA (cDNA clone IMAGE:5117478) [BC034004] KLA .69 .72 .63 .69 .68 .81 .61
ATP .91 .86 1.29 .96 .81 .94 .51
KLA/ATP .62 .54 .85 .64 .70 .75 .44
Pole3
KLA  ATP  ATP+KLA
 NM_021498 polymerase (DNA directed), epsilon 3 (p17 subunit) (Pole3), mRNA [NM_021498] KLA 1.14 1.14 1.23 1.36 1.18 1.15 1.01
ATP 1.02 .98 1.17 1.44 1.40 1.27 1.25
KLA/ATP 1.20 1.24 1.58 1.57 1.60 1.25 1.23
Pole4
KLA  ATP  ATP+KLA
 NM_025882 polymerase (DNA-directed), epsilon 4 (p12 subunit) (Pole4), mRNA [NM_025882] KLA 1.11 1.15 1.15 1.22 1.19 1.31 1.26
ATP 1.00 .99 1.36 1.32 1.34 1.19 .98
KLA/ATP 1.02 1.15 1.58 1.47 1.52 1.10 .85
Ppp3ca
KLA  ATP  ATP+KLA
 NM_008913 protein phosphatase 3, catalytic subunit, alpha isoform (Ppp3ca), mRNA [NM_008913] KLA .76 .85 .81 .85 .73 .70 .52
ATP .96 .78 .55 .46 .31 .33 .48
KLA/ATP .74 .64 .52 .42 .37 .36 .45
Ppp3cb
KLA  ATP  ATP+KLA
 AK135203 12 days embryo male wolffian duct includes surrounding region cDNA, RIKEN full-length enriched library, clone:6720421K10 product:protein phosphatase 3, catalytic subunit, beta isoform, full insert sequence. [AK135203] KLA 1.74 1.57 1.91 1.59 1.47 1.26 1.40
ATP 1.17 1.03 1.30 1.00 .81 .62 1.37
KLA/ATP 1.68 1.70 1.91 1.37 1.09 .47 1.13
Ppp3cb
KLA  ATP  ATP+KLA
 AK171904 activated spleen cDNA, RIKEN full-length enriched library, clone:F830018L06 product:Protein phosphatase 3 catalytic subunit beta3 (EC 3.1.3.16) (Serine [AK171904] KLA 1.29 1.29 1.21 1.15 1.22 1.13 1.28
ATP .90 .86 .80 .98 .94 .73 .92
KLA/ATP 1.06 1.03 .77 1.04 .92 .68 .90
Ppp3cb
KLA  ATP  ATP+KLA
 NM_008914 protein phosphatase 3, catalytic subunit, beta isoform (Ppp3cb), mRNA [NM_008914] KLA 1.21 1.29 1.38 1.24 1.29 1.08 1.23
ATP 1.15 1.31 1.09 1.29 .86 .60 .64
KLA/ATP 1.33 1.40 1.04 1.28 .79 .58 .73
Ppp3cc
KLA  ATP  ATP+KLA
 AK037563 16 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A130026K22 product:unclassifiable, full insert sequence [AK037563] KLA 1.27 1.18 1.21 1.15 1.01 .92 1.36
ATP .96 1.09 1.10 1.03 .85 1.06 1.47
KLA/ATP 1.17 1.24 1.07 1.13 .91 .88 1.36
Ppp3cc
KLA  ATP  ATP+KLA
 NM_008915 protein phosphatase 3, catalytic subunit, gamma isoform (Ppp3cc), mRNA [NM_008915] KLA 1.64 1.81 1.79 1.35 .90 .70 1.31
ATP .90 .90 1.13 .93 .86 1.40 1.60
KLA/ATP 1.45 1.62 1.74 1.47 1.04 1.01 1.31
Ppp3r1
KLA  ATP  ATP+KLA
 NM_024459 protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type I) (Ppp3r1), mRNA [NM_024459] KLA 1.02 1.17 .93 1.27 1.15 1.30 1.30
ATP .97 .95 .77 .91 .99 1.18 1.10
KLA/ATP 1.12 1.04 .88 1.00 1.10 1.10 1.07
Ppp3r2
KLA  ATP  ATP+KLA
 NM_001004025 protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type II) (Ppp3r2), mRNA [NM_001004025] KLA 1.03 1.05 1.06 1.08 1.12 1.05 1.04
ATP 1.00 1.02 1.04 1.04 .99 .99 1.01
KLA/ATP 1.04 1.12 1.03 1.09 1.00 .99 1.00
Prkaca
KLA  ATP  ATP+KLA
 NM_008854 protein kinase, cAMP dependent, catalytic, alpha (Prkaca), mRNA [NM_008854] KLA .71 .74 .72 .70 .72 .84 .85
ATP 1.05 .98 .89 .92 .76 .60 1.02
KLA/ATP .79 .74 .55 .65 .60 .65 .93
Prkacb
KLA  ATP  ATP+KLA
 NM_011100 protein kinase, cAMP dependent, catalytic, beta (Prkacb), mRNA [NM_011100] KLA .69 .70 .66 .58 .51 .55 .59
ATP 1.02 1.19 .97 1.01 .69 .38 .56
KLA/ATP .72 .73 .57 .62 .47 .41 .45
Prkx
KLA  ATP  ATP+KLA
 NM_016979 protein kinase, X-linked (Prkx), mRNA [NM_016979] KLA 3.61 3.79 4.67 4.66 4.85 4.19 1.43
ATP .98 .90 .63 .61 1.12 1.90 1.29
KLA/ATP 3.56 3.36 2.62 2.06 2.26 2.87 2.31
Pttg1
KLA  ATP  ATP+KLA
 NM_013917 pituitary tumor-transforming 1 (Pttg1), mRNA [NM_013917] KLA 3.06 2.73 3.51 4.09 3.52 2.99 2.09
ATP 1.06 .94 1.23 1.15 1.33 2.08 1.43
KLA/ATP 3.07 2.93 4.25 3.27 4.24 4.01 3.35
Ran
KLA  ATP  ATP+KLA
 NM_009391 RAN, member RAS oncogene family (Ran), mRNA [NM_009391] KLA .96 1.03 .96 .88 .78 .61 .75
ATP .96 .96 1.04 .87 1.10 1.18 .64
KLA/ATP .96 .97 .99 .84 1.03 .91 .61
Ranbp1
KLA  ATP  ATP+KLA
 X56045 gb|Mouse mRNA (clone lambda-19) for hypothetical protein A. [X56045] KLA 1.28 1.17 1.28 1.33 1.15 .99 .60
ATP 1.10 1.02 1.31 1.26 1.18 .76 .40
KLA/ATP 1.19 1.29 1.72 1.62 1.87 1.33 .30
Ranbp3
KLA  ATP  ATP+KLA
 AK154201 NOD-derived CD11c +ve dendritic cells cDNA, RIKEN full-length enriched library, clone:F630008P20 product:unclassifiable, full insert sequence [AK154201] KLA .86 .86 .87 .98 1.20 1.11 1.00
ATP 1.10 1.32 1.02 .77 1.84 1.33 1.04
KLA/ATP .99 1.04 .87 .82 1.80 1.19 1.06
Ranbp3
KLA  ATP  ATP+KLA
 NM_027933 RAN binding protein 3 (Ranbp3), mRNA [NM_027933] KLA .97 1.01 .99 1.03 1.11 1.25 1.14
ATP .91 .98 1.05 .99 1.18 1.36 1.12
KLA/ATP .99 1.01 1.08 1.00 1.27 1.48 1.39
Rasl2-9
KLA  ATP  ATP+KLA
 NM_009028 RAS-like, family 2, locus 9 (Rasl2-9), mRNA [NM_009028] KLA .94 1.01 1.05 .89 .81 .62 .70
ATP 1.05 1.05 1.13 .99 1.25 1.24 .68
KLA/ATP 1.00 .98 1.12 .94 1.10 .90 .67
Rb1
KLA  ATP  ATP+KLA
 NM_009029 retinoblastoma 1 (Rb1), mRNA [NM_009029] KLA .67 .60 .55 .51 .46 .75 .79
ATP 1.04 1.01 1.12 .86 .59 .43 .76
KLA/ATP .64 .59 .58 .46 .36 .30 .65
Rela
KLA  ATP  ATP+KLA
 NM_009045 v-rel reticuloendotheliosis viral oncogene homolog A (avian) (Rela), mRNA [NM_009045] KLA 2.05 2.05 2.07 1.75 1.83 1.58 1.33
ATP 1.03 1.08 1.10 1.44 1.61 2.48 1.05
KLA/ATP 2.17 2.27 2.05 2.47 1.93 2.35 2.02
Relb
KLA  ATP  ATP+KLA
 NM_009046 avian reticuloendotheliosis viral (v-rel) oncogene related B (Relb), mRNA [NM_009046] KLA 4.39 4.46 3.54 3.47 4.36 3.18 2.72
ATP 1.01 1.07 1.23 2.66 3.23 3.50 1.24
KLA/ATP 4.43 4.52 3.56 4.10 2.85 2.92 3.30
Rras
KLA  ATP  ATP+KLA
 NM_009101 Harvey rat sarcoma oncogene, subgroup R (Rras), mRNA [NM_009101] KLA .89 .89 .99 .98 1.25 1.48 1.81
ATP 1.14 1.17 1.01 1.61 1.37 1.33 1.40
KLA/ATP 1.09 1.05 1.01 1.34 1.24 1.10 1.27
Rras2
KLA  ATP  ATP+KLA
 NM_025846 related RAS viral (r-ras) oncogene homolog 2 (Rras2), mRNA [NM_025846] KLA 7.72 7.35 7.03 5.47 3.21 1.03 .65
ATP .92 .86 .99 .95 1.86 2.13 .72
KLA/ATP 6.51 6.50 5.94 4.45 3.05 1.72 .75
Sfpi1
KLA  ATP  ATP+KLA
 NM_011355 SFFV proviral integration 1 (Sfpi1), mRNA [NM_011355] KLA 2.54 2.77 2.96 2.31 3.22 2.44 2.29
ATP 1.17 1.55 .79 1.96 1.49 1.23 1.66
KLA/ATP 3.35 3.40 1.30 3.78 1.70 1.80 3.18
Slc25a31
KLA  ATP  ATP+KLA
 NM_178386 solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 31 (Slc25a31), nuclear gene encoding mitochondrial protein, mRNA [NM_178386] KLA .99 .96 .88 .97 .96 .91 .75
ATP 1.09 .96 .96 1.01 .92 .90 .77
KLA/ATP 1.02 .96 .89 .90 .96 .93 .74
Slc25a4
KLA  ATP  ATP+KLA
 NM_007450 solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), member 4 (Slc25a4), nuclear gene encoding mitochondrial protein, mRNA [NM_007450] KLA .80 .84 .85 .80 .77 .70 .68
ATP 1.01 1.04 .99 1.00 .81 .46 .60
KLA/ATP .88 .85 .77 .78 .65 .42 .23
Slc25a5
KLA  ATP  ATP+KLA
 NM_007451 solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), member 5 (Slc25a5), nuclear gene encoding mitochondrial protein, mRNA [NM_007451] KLA .93 .93 .89 .90 .93 .92 1.27
ATP 1.03 1.08 .93 .97 .98 .92 1.06
KLA/ATP .84 .91 .80 .87 .75 .76 .55
Slc2a1
KLA  ATP  ATP+KLA
 NM_011400 solute carrier family 2 (facilitated glucose transporter), member 1 (Slc2a1), mRNA [NM_011400] KLA 1.31 1.46 1.10 1.68 1.75 1.95 2.34
ATP .88 .90 1.32 1.99 3.40 10.49 1.93
KLA/ATP 1.13 1.25 1.71 2.14 3.71 6.31 4.63
Smad2
KLA  ATP  ATP+KLA
 NM_010754 MAD homolog 2 (Drosophila) (Smad2), mRNA [NM_010754] KLA 1.05 1.08 1.04 1.17 1.40 1.43 1.59
ATP 1.01 1.02 1.16 1.14 1.15 1.32 1.34
KLA/ATP 1.00 .99 .97 1.09 1.40 1.14 1.40
Smad3
KLA  ATP  ATP+KLA
 NM_016769 MAD homolog 3 (Drosophila) (Smad3), mRNA [NM_016769] KLA .64 .60 .57 .64 .70 1.25 1.52
ATP 1.02 1.02 .84 1.21 2.42 .90 1.19
KLA/ATP .64 .60 .65 .66 1.29 1.26 2.26
Smad4
KLA  ATP  ATP+KLA
 NM_008540 MAD homolog 4 (Drosophila) (Smad4), mRNA [NM_008540] KLA 1.11 1.11 1.13 1.09 1.02 .98 1.08
ATP 1.00 1.04 .92 .76 1.67 1.44 .92
KLA/ATP 1.09 1.01 .87 .89 1.64 1.43 .99
Srf
KLA  ATP  ATP+KLA
 NM_020493 serum response factor (Srf), mRNA [NM_020493] KLA .56 .53 .61 .82 1.37 1.04 .70
ATP 1.13 .88 .71 .68 .86 .85 .50
KLA/ATP .61 .51 .46 .42 .82 .99 .47
Stat5a
KLA  ATP  ATP+KLA
 NM_011488 signal transducer and activator of transcription 5A (Stat5a), mRNA [NM_011488] KLA 8.23 8.24 6.89 4.88 4.35 1.98 1.01
ATP 1.07 1.14 1.07 1.26 3.23 3.14 1.52
KLA/ATP 8.70 9.53 7.33 6.68 4.32 2.73 1.72
Stat5b
KLA  ATP  ATP+KLA
 AK137889 16 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A130035C01 product:unclassifiable, full insert sequence. [AK137889] KLA 1.10 1.01 .98 .90 1.03 .93 .88
ATP .90 .87 .61 .69 1.01 .97 .89
KLA/ATP 1.12 1.00 .87 .85 .95 1.07 .83
Stat5b
KLA  ATP  ATP+KLA
 NM_011489 signal transducer and activator of transcription 5B (Stat5b), transcript variant 1, mRNA [NM_011489] KLA 2.91 2.81 3.42 2.69 2.23 1.95 1.32
ATP .99 1.04 1.16 .97 1.00 1.84 2.09
KLA/ATP 2.96 3.05 3.17 2.99 1.86 1.87 3.40
Tbp
KLA  ATP  ATP+KLA
 NM_013684 TATA box binding protein (Tbp), mRNA [NM_013684] KLA 1.27 1.33 1.42 1.17 1.23 1.20 1.22
ATP 1.07 1.21 1.01 .85 .93 1.04 1.14
KLA/ATP 1.38 1.40 1.13 1.11 .93 1.13 1.12
Tbpl1
KLA  ATP  ATP+KLA
 AK028621 10 days neonate skin cDNA, RIKEN full-length enriched library, clone:4732418P20 product:TATA box binding protein-like protein, full insert sequence [AK028621] KLA 1.03 1.11 .99 .98 .97 .88 .92
ATP .95 1.03 1.05 .94 .94 .96 1.09
KLA/ATP .98 .95 .99 .98 .98 1.03 1.01
Tbpl1
KLA  ATP  ATP+KLA
 NM_011603 TATA box binding protein-like 1 (Tbpl1), mRNA [NM_011603] KLA .68 .72 .72 .71 .76 .87 1.05
ATP .93 .97 .98 .89 1.05 .97 .85
KLA/ATP .67 .66 .74 .70 1.04 1.20 1.00
Tbpl2
KLA  ATP  ATP+KLA
 NM_199059 TATA box binding protein like 2 (Tbpl2), mRNA [NM_199059] KLA 1.01 1.10 .97 1.00 .92 .96 1.04
ATP 1.01 1.03 1.04 1.02 .95 1.00 1.02
KLA/ATP 1.04 .92 .83 1.06 1.03 1.02 .97
Tcfe2a
KLA  ATP  ATP+KLA
 NM_011548 transcription factor E2a (Tcfe2a), mRNA [NM_011548] KLA .72 .66 .57 .57 .65 .73 .75
ATP 1.11 1.26 .97 1.15 .69 .71 .84
KLA/ATP .61 .70 .58 .69 .50 .62 .66
Tert
KLA  ATP  ATP+KLA
 NM_009354 telomerase reverse transcriptase (Tert), mRNA [NM_009354] KLA .99 1.08 .95 1.05 1.02 1.07 1.04
ATP .96 .99 1.08 1.00 .99 .98 1.02
KLA/ATP .94 1.06 1.09 .95 1.03 1.01 .93
Tgfb1
KLA  ATP  ATP+KLA
 NM_011577 transforming growth factor, beta 1 (Tgfb1), mRNA [NM_011577] KLA .87 .89 .90 .70 .83 .77 1.12
ATP 1.20 1.41 .80 1.49 1.11 .93 .99
KLA/ATP 1.10 1.20 .53 1.05 .66 .85 .90
Tgfb2
KLA  ATP  ATP+KLA
 NM_009367 transforming growth factor, beta 2 (Tgfb2), mRNA [NM_009367] KLA 1.01 .91 .98 .98 .92 1.19 .96
ATP .99 1.03 1.00 1.02 .99 1.07 .93
KLA/ATP 1.02 .99 1.03 .98 1.04 1.06 .96
Tgfb3
KLA  ATP  ATP+KLA
 NM_009368 transforming growth factor, beta 3 (Tgfb3), mRNA [NM_009368] KLA .67 .64 .58 .56 .49 .52 .61
ATP .90 .92 1.33 1.08 .78 .65 .74
KLA/ATP .58 .60 .74 .61 .76 1.36 1.51
Tgfbr1
KLA  ATP  ATP+KLA
 NM_009370 transforming growth factor, beta receptor I (Tgfbr1), mRNA [NM_009370] KLA .73 .74 .59 .54 .52 .64 .84
ATP .99 1.12 .99 1.16 1.22 .84 .93
KLA/ATP .75 .78 .58 .64 .62 .59 .77
Tgfbr2
KLA  ATP  ATP+KLA
 AK090393 10 days pregnant adult female ovary and uterus cDNA, RIKEN full-length enriched library, clone:G630098D03 product:transforming growth factor, beta receptor II, full insert sequence. [AK090393] KLA .98 .89 1.00 .96 .94 1.00 .92
ATP .99 .99 .90 .94 .93 .96 1.02
KLA/ATP .92 .96 .98 .98 .98 .95 1.01
Tgfbr2
KLA  ATP  ATP+KLA
 NM_009371 transforming growth factor, beta receptor II (Tgfbr2), transcript variant 1, mRNA [NM_009371] KLA .55 .50 .58 .50 .52 .55 .44
ATP .98 .75 .50 .32 .41 .29 .50
KLA/ATP .59 .45 .32 .23 .31 .27 .25
Tgfbr2
KLA  ATP  ATP+KLA
 NM_029575 transforming growth factor, beta receptor II (Tgfbr2), transcript variant 2, mRNA [NM_029575] KLA .95 .93 .99 .95 .88 1.02 .82
ATP .87 .93 .84 .84 .74 .72 1.00
KLA/ATP .89 .85 .83 .85 .76 .80 .79
Tln1
KLA  ATP  ATP+KLA
 NM_011602 talin 1 (Tln1), mRNA [NM_011602] KLA .95 1.02 1.10 .90 1.30 1.13 .92
ATP 1.14 1.35 .60 .92 .76 .60 .89
KLA/ATP 1.21 1.18 .51 .77 .55 .70 1.20
Tln2
KLA  ATP  ATP+KLA
 NM_001081242 talin 2 (Tln2), mRNA [NM_001081242] KLA 1.03 1.01 .98 1.03 .96 .93 .94
ATP 1.01 .97 .98 1.00 .93 .87 .97
KLA/ATP 1.00 .99 1.03 .98 .87 .84 .89
Tnf
KLA  ATP  ATP+KLA
 NM_013693 tumor necrosis factor (Tnf), mRNA [NM_013693] KLA 13.35 12.76 10.71 9.03 10.64 7.39 8.32
ATP 2.01 2.48 8.27 19.20 9.72 4.09 1.49
KLA/ATP 12.72 15.76 12.73 17.34 5.10 3.61 6.07
Tnfrsf13
c
KLA  ATP  ATP+KLA
 NM_028075 tumor necrosis factor receptor superfamily, member 13c (Tnfrsf13c), mRNA [NM_028075] KLA 1.05 1.04 1.05 1.01 1.05 1.00 .92
ATP 1.03 1.01 1.01 .99 1.04 1.03 1.04
KLA/ATP 1.05 1.07 1.10 1.04 1.02 .94 1.00
Tnfrsf1a
KLA  ATP  ATP+KLA
 NM_011609 tumor necrosis factor receptor superfamily, member 1a (Tnfrsf1a), mRNA [NM_011609] KLA 1.74 1.71 1.90 2.16 1.95 1.74 1.16
ATP .95 .83 .55 .41 .41 1.55 1.32
KLA/ATP 1.58 1.49 1.19 1.03 .98 2.02 2.10
Trp53
KLA  ATP  ATP+KLA
 NM_011640 transformation related protein 53 (Trp53), mRNA [NM_011640] KLA 1.25 1.37 1.11 .86 .72 .71 .95
ATP 1.15 1.32 .90 1.85 1.26 .68 .70
KLA/ATP 1.66 1.49 .80 1.76 .81 .65 .74
Trp53inp
1
KLA  ATP  ATP+KLA
 NM_021897 transformation related protein 53 inducible nuclear protein 1 (Trp53inp1), mRNA [NM_021897] KLA .92 .81 .74 .63 .51 .57 .33
ATP 1.00 1.01 .90 .76 .98 1.50 .35
KLA/ATP .87 .85 .88 .71 1.01 1.52 .71
Trrap
KLA  ATP  ATP+KLA
 NM_001081362 transformation/transcription domain-associated protein (Trrap), mRNA [NM_001081362] KLA .97 .88 .86 .91 1.15 1.23 1.13
ATP 1.10 1.16 1.00 1.08 1.27 1.89 .99
KLA/ATP .97 1.03 .86 1.05 1.45 2.04 1.32
Tspo
KLA  ATP  ATP+KLA
 NM_009775 translocator protein (Tspo), mRNA [NM_009775] KLA 2.43 2.59 2.88 3.03 4.05 4.37 4.80
ATP 1.15 1.16 .97 1.30 1.13 1.25 2.08
KLA/ATP 2.72 2.79 2.51 3.45 2.78 3.22 5.46
Vac14
KLA  ATP  ATP+KLA
 AK011396 10 days embryo whole body cDNA, RIKEN full-length enriched library, clone:2610014M01 product:unclassifiable, full insert sequence. [AK011396] KLA .83 .81 .80 .90 1.01 .87 1.17
ATP 1.24 1.12 1.03 .92 1.45 .95 1.23
KLA/ATP .88 .99 .96 .79 1.28 .93 1.07
Vac14
KLA  ATP  ATP+KLA
 NM_146216 Vac14 homolog (S. cerevisiae) (Vac14), mRNA [NM_146216] KLA .80 .86 .91 .78 .82 .96 1.26
ATP .97 1.07 .81 1.07 .88 .72 1.10
KLA/ATP .89 .80 .59 .77 .64 .78 .87
Vcam1
KLA  ATP  ATP+KLA
 NM_011693 vascular cell adhesion molecule 1 (Vcam1), mRNA [NM_011693] KLA 18.71 22.30 20.87 18.09 13.61 6.09 2.09
ATP 1.08 1.00 1.56 4.23 5.09 5.04 1.50
KLA/ATP 19.09 25.02 26.43 25.42 20.08 11.45 6.67
Vdac1
KLA  ATP  ATP+KLA
 NM_011694 voltage-dependent anion channel 1 (Vdac1), mRNA [NM_011694] KLA .85 .86 .95 .80 .69 .62 .76
ATP .93 1.01 1.32 1.01 .96 .82 .57
KLA/ATP .81 .85 1.05 .78 .78 .78 .48
Vdac2
KLA  ATP  ATP+KLA
 NM_011695 voltage-dependent anion channel 2 (Vdac2), mRNA [NM_011695] KLA .92 .89 .80 .96 .85 .97 .83
ATP .84 .72 .75 .54 .52 .48 .72
KLA/ATP .74 .68 .71 .48 .69 .59 .37
Vdac3
KLA  ATP  ATP+KLA
 NM_011696 voltage-dependent anion channel 3 (Vdac3), mRNA [NM_011696] KLA 1.09 1.11 1.13 1.15 1.12 1.21 1.45
ATP .95 .96 1.06 .91 .91 1.36 1.11
KLA/ATP 1.06 1.06 1.20 1.03 1.11 1.07 1.12
Wnt1
KLA  ATP  ATP+KLA
 NM_021279 wingless-related MMTV integration site 1 (Wnt1), mRNA [NM_021279] KLA 1.01 1.01 1.05 1.03 1.04 1.04 1.01
ATP .99 .99 1.01 .97 .96 1.01 1.00
KLA/ATP 1.01 1.04 1.06 1.02 1.00 .98 .98
Wnt10a
KLA  ATP  ATP+KLA
 NM_009518 wingless related MMTV integration site 10a (Wnt10a), mRNA [NM_009518] KLA 1.73 1.66 1.33 1.17 1.10 1.02 1.03
ATP 1.03 1.04 .93 1.02 1.04 1.07 1.06
KLA/ATP 1.83 1.67 1.53 1.21 1.10 1.12 1.09
Wnt10b
KLA  ATP  ATP+KLA
 NM_011718 wingless related MMTV integration site 10b (Wnt10b), mRNA [NM_011718] KLA 1.10 .98 1.13 1.01 .96 1.00 .96
ATP 1.02 1.02 .99 1.01 .96 1.02 1.01
KLA/ATP 1.01 1.18 .97 .97 1.03 1.04 .98
Wnt11
KLA  ATP  ATP+KLA
 NM_009519 wingless-related MMTV integration site 11 (Wnt11), mRNA [NM_009519] KLA .97 1.00 .97 1.03 1.16 1.08 1.11
ATP 1.03 1.06 1.08 1.23 1.13 1.03 1.08
KLA/ATP .95 1.00 .95 1.02 .97 1.04 1.04
Wnt16
KLA  ATP  ATP+KLA
 NM_053116 wingless-related MMTV integration site 16 (Wnt16), mRNA [NM_053116] KLA 1.00 1.02 .97 1.02 .96 1.02 1.05
ATP 1.01 1.00 .97 .98 .97 .95 1.02
KLA/ATP .96 1.01 .98 1.03 .99 1.00 .97
Wnt2
KLA  ATP  ATP+KLA
 NM_023653 wingless-related MMTV integration site 2 (Wnt2), mRNA [NM_023653] KLA 1.01 1.00 1.02 .96 1.06 1.03 .94
ATP .97 1.01 1.02 .98 1.00 1.05 1.01
KLA/ATP .97 .94 1.03 1.02 1.00 .99 1.05
Wnt2b
KLA  ATP  ATP+KLA
 NM_009520 wingless related MMTV integration site 2b (Wnt2b), mRNA [NM_009520] KLA 1.04 1.03 .99 1.01 .95 1.02 .99
ATP .95 1.00 .95 .99 .97 1.03 1.01
KLA/ATP 1.02 .99 1.01 1.06 .99 .99 1.02
Wnt3
KLA  ATP  ATP+KLA
 NM_009521 wingless-related MMTV integration site 3 (Wnt3), mRNA [NM_009521] KLA 1.04 1.02 1.04 1.02 1.00 .99 1.00
ATP 1.03 .98 1.04 1.04 .96 1.00 1.02
KLA/ATP 1.03 .99 .98 1.03 1.04 .94 1.03
Wnt3a
KLA  ATP  ATP+KLA
 NM_009522 wingless-related MMTV integration site 3A (Wnt3a), mRNA [NM_009522] KLA 1.01 1.00 1.06 1.02 .99 1.02 .99
ATP .96 .97 1.05 1.04 1.02 1.02 1.04
KLA/ATP 1.02 1.03 .96 1.01 .99 1.06 1.00
Wnt4
KLA  ATP  ATP+KLA
 NM_009523 wingless-related MMTV integration site 4 (Wnt4), mRNA [NM_009523] KLA 1.01 1.01 .97 1.06 1.12 1.02 .93
ATP 1.02 1.06 1.03 1.02 1.00 1.02 .98
KLA/ATP .94 1.01 1.06 1.05 .96 .96 1.00
Wnt5a
KLA  ATP  ATP+KLA
 NM_009524 wingless-related MMTV integration site 5A (Wnt5a), mRNA [NM_009524] KLA .98 1.06 1.01 .96 1.03 1.02 1.07
ATP 1.01 .96 1.06 1.11 1.02 .97 1.03
KLA/ATP 1.05 .96 .96 1.04 1.12 1.06 .96
Wnt5b
KLA  ATP  ATP+KLA
 NM_009525 wingless-related MMTV integration site 5B (Wnt5b), mRNA [NM_009525] KLA 1.04 1.04 1.19 1.11 1.10 1.11 1.05
ATP 1.04 1.01 .95 1.01 .99 1.04 1.05
KLA/ATP 1.05 1.06 1.11 1.07 1.04 1.08 1.05
Wnt6
KLA  ATP  ATP+KLA
 M89800 gb|Mouse Wnt-6 mRNA, complete cds. [M89800] KLA 1.92 1.97 1.93 2.04 2.01 2.62 5.22
ATP .96 .97 1.07 1.03 .76 .94 1.18
KLA/ATP 2.04 1.91 1.96 1.72 1.40 1.31 2.45
Wnt6
KLA  ATP  ATP+KLA
 NM_009526 wingless-related MMTV integration site 6 (Wnt6), mRNA [NM_009526] KLA 2.83 2.51 2.19 2.74 2.92 3.01 5.82
ATP 1.01 .87 1.07 .77 .59 1.11 1.06
KLA/ATP 2.31 2.49 2.69 1.79 1.63 1.26 2.64
Wnt7a
KLA  ATP  ATP+KLA
 NM_009527 wingless-related MMTV integration site 7A (Wnt7a), mRNA [NM_009527] KLA .96 .92 .91 .99 .96 .98 .97
ATP 1.05 .95 .98 .98 1.03 .98 1.11
KLA/ATP .92 .89 .88 .97 1.01 1.04 1.01
Wnt7b
KLA  ATP  ATP+KLA
 NM_009528 wingless-related MMTV integration site 7B (Wnt7b), mRNA [NM_009528] KLA 1.06 1.09 .99 1.09 1.06 1.19 1.26
ATP .99 .98 1.02 1.08 1.02 1.11 1.54
KLA/ATP 1.02 1.01 .99 1.14 1.07 1.09 1.58
Wnt8a
KLA  ATP  ATP+KLA
 NM_009290 wingless-related MMTV integration site 8A (Wnt8a), mRNA [NM_009290] KLA .92 1.01 .99 1.00 1.06 1.01 1.04
ATP 1.00 1.01 1.01 1.04 1.00 1.06 1.05
KLA/ATP 1.07 1.05 .99 1.08 1.07 1.09 1.07
Wnt8b
KLA  ATP  ATP+KLA
 NM_011720 wingless related MMTV integration site 8b (Wnt8b), mRNA [NM_011720] KLA 1.00 1.00 .94 1.03 .98 .98 .97
ATP .99 1.01 1.01 1.01 1.05 1.04 1.03
KLA/ATP .98 1.03 1.00 1.01 .99 1.02 1.02
Wnt9a
KLA  ATP  ATP+KLA
 NM_139298 wingless-type MMTV integration site 9A (Wnt9a), mRNA [NM_139298] KLA .93 .95 .95 1.01 .96 .97 1.01
ATP 1.01 .98 1.01 1.08 1.43 1.02 1.44
KLA/ATP .94 .96 1.03 1.15 1.43 1.15 1.21
Wnt9b
KLA  ATP  ATP+KLA
 NM_011719 wingless-type MMTV integration site 9B (Wnt9b), mRNA [NM_011719] KLA .97 1.00 .94 1.00 .99 .97 1.02
ATP .96 1.02 1.05 .99 .92 1.11 1.08
KLA/ATP .97 .96 .99 .93 .96 1.03 .99
Xbp1
KLA  ATP  ATP+KLA
 NM_013842 X-box binding protein 1 (Xbp1), mRNA [NM_013842] KLA .95 .98 1.13 1.28 1.50 .97 1.46
ATP 1.32 1.37 .75 .85 .97 .77 1.22
KLA/ATP 1.16 1.29 .80 1.08 .81 .97 .88
Xiap
KLA  ATP  ATP+KLA
 NM_009688 X-linked inhibitor of apoptosis (Xiap), mRNA [NM_009688] KLA 1.61 1.63 1.62 1.52 1.34 1.27 1.11
ATP 1.03 1.01 .99 .96 .88 1.19 1.25
KLA/ATP 1.64 1.63 1.54 1.33 1.08 1.19 1.72
Xpo1
KLA  ATP  ATP+KLA
 NM_134014 exportin 1, CRM1 homolog (yeast) (Xpo1), transcript variant 1, mRNA [NM_134014] KLA .85 .84 .92 .94 1.07 1.07 .94
ATP 1.00 .97 .86 .74 .61 .56 .77
KLA/ATP .87 .81 .71 .66 .70 .74 .77
Zfp36
KLA  ATP  ATP+KLA
 NM_011756 zinc finger protein 36 (Zfp36), mRNA [NM_011756] KLA 3.30 3.27 3.79 4.20 4.08 3.01 2.48
ATP 1.84 2.37 4.35 6.29 3.62 2.97 1.85
KLA/ATP 4.16 5.16 7.00 7.83 5.54 4.48 5.73